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ABSTRACT 
Mast cells are classically recognized as the effector cells of Immunoglobulin E 
(IgE)-mediated hypersensitivity reactions (i.e. allergic reactions). Mast cells also play an 
important role in the innate immune response to parasitic helminth infection. Allergic 
disease including allergic rhinitis, asthma, atopic dermatitis, and anaphylaxis, is a major 
health concern in the United States with greater than 60 million Americans suffering 
from allergy and asthma. In addition, mast cells have more recently been implicated in 
non-allergic disease including various human cancers, which will affect approximately 
39.6% of U.S. men and women. Therefore, understanding the immunological and 
molecular mechanisms that regulate mast cells is vital to our understanding of their role 
in both allergic and non-allergic disease in humans. In this study, we identified novel 
mechanisms that regulate FcεRI-induced biosynthesis of inflammatory Prostaglandin D2 
(PGD2) from in situ-matured mast cells from human skin. Specifically, we demonstrated 
that interleukin-6 (IL-6), a classical pro-inflammatory cytokine, is a positive regulator, 
whereas Resveratrol, a natural polyphenol found in the skin of red grapes, is a negative 
regulator of PGD2 biosynthesis. We demonstrate that Resveratrol at relatively low 
concentrations specifically inhibited the production of PGD2 without affecting 
degranulation. Mechanistically, Resveratrol inhibited the expression of cyclooxygenase-2 
(COX-2), an enzyme in the arachidonic acid pathway that is directly involved in PGD2 
biosynthesis, but had no effect on phosphorylation of Syk kinase, which is a critical 
protein in mast cell degranulation. In contrast, IL-6 enhanced FcεRI-induced COX-2 
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expression leading to increased PGD2 biosynthesis. In support of this, we showed 
that FcεRI and gp130 (the signaling portion of the IL-6 receptor) signals cooperate to 
enhance STAT-3 phosphorylation, a key event in the IL-6 receptor signal pathway. 
Moreover, inhibition of IL-6-induced phosphorylation of STAT-3 with the specific 
inhibitor C188-9 also attenuated the increased production of PGD2. Thus, IL-6 
potentiates PGD2 production by a STAT-3-dependent mechanism. Jointly, these data 
demonstrate that Resveratrol is a negative regulator, and IL-6 a positive regulator of 
FcεRI-induced PGD2 biosynthesis from human skin mast cells. We further demonstrate 
that IL-6 induced the expression of vascular endothelial growth factor (VEGF), a major 
regulator of angiogenesis, from human skin mast cells also by a STAT-3-dependent 
mechanism. Lastly, we demonstrated by proteome profiling analysis that human skin 
mast cells spontaneously secrete several angiogenesis-related proteins – CXCL16, 
DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP-
1, Thrombospondin-1, uPA, and VEGF – at relatively high concentrations. The array data 
was verified by specific enzyme linked immunoassay (ELISA). This novel data suggests 
an innate role for mast cells in both human tumorigenesis and normal development of 
human vasculature. Together, these novel findings enhance our understanding of the 
mechanisms that regulate the release of allergic mediators from mast cells, and suggest a 
possible role for mast cells in oncogenesis and normal vascular development.
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 Recently, mast cells have been implicated in many non-allergic diseases in which 
chronic inflammation plays a vital role (1–3). While they are traditionally viewed as the 
effector cells of IgE-mediated hypersensitivity responses, mast cells undoubtedly have 
yet undefined functions outside of these mechanisms. One of the most critical areas of 
mast cell biology to understand is the modulation of inflammatory mediator release. Due 
to their ability to produce and release robust quantities of many different chemical 
mediators, mast cells can affect a wide variety of processes such as cell migration, vessel 
formation and dilation, airway constriction, and mucous production (4).  
1.1 MAST CELLS 
Mast cells are hematopoietic immune cells that function as the effector cells of the 
allergic reaction in addition to participating in the innate immune response against 
infection (5). Mast cells can be characterized by three distinct features: the surface 
expression of the high-affinity IgE receptor FcεRI,  surface expression of the stem cell 
factor (SCF) receptor, and numerous cytoplasmic granules containing pre-formed 
inflammatory mediators (6). These tissue-resident sentinel cells use their complement of 
chemical mediators to induce and modulate a wide range of physiological processes 
including anaphylaxis, angiogenesis, and wound-healing (7).   
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Mast cell development begins in the bone marrow where hematopoietic stem cells 
develop into multipotent progenitors. The multipotent progenitors then undergo 
commitment into mast cell progenitors (MCp) through careful transcriptional control. 
MCps are then released into circulation already both c-kit and FcεRI positive, but are 
nearly unidentifiable by classical staining due to their reduced or non-existent granularity. 
From circulation, MCps home to the peripheral tissues, particularly to areas that directly 
contact the external environment and around vessels, where they become resident and 
mature in-situ (8, 9). During the process of migration, maturation, and survival of the 
mast cell progenitors, the cytokine stem cell factor (SCF) is indispensable (10). SCF is 
the ligand for c-kit (CD117), and binding of the receptor leads to the activation of the 
JAK/STAT, PI3K/AKT/mTOR, and RAS/RAF/MAPK pathways (11). Together, the 
gene products of these pathways cooperate to trigger mast cell proliferation, migration, 
and progression through the cell cycle (12). SCF is also necessary for mast cell survival 
(13). It has also been shown that SCF is necessary for murine mast cells to develop a full 
complement of cytoplasmic granules (14, 15). 
Once mature, mast cells are generally considered to be very long-lived (6). 
Interestingly, mature tissue mast cells are believed to be terminally differentiated and 
thus do not normally undergo cell division and proliferation (8). Mast cells also tend to 
exhibit heterogeneity that seems to be influenced by the tissue in which they mature (16, 
17). This is most evident in the enzyme content of their granules, as human lung mast 
cells express only tryptase (MCT) while human skin mast cells contain both tryptase and 
chymase in their granules (MCTC) (18). In the border tissues, the main role of mast cells 
is to become sensitized to invaders by binding IgE with FcεRI, enabling them to react to 
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exposure from foreign compounds. The pathway initiated by FcεRI crosslinking (XL) in 
mast cells is complicated, but ultimately results in the release of the cytoplasmic granules 
and their mediators, biosynthesis of membrane-derived eicosanoids, and de-novo 
synthesis of inflammatory proteins (19).  
Upon crosslinking by a multivalent antigen and subsequent receptor aggregation, 
the immunoreceptor tyrosine-based activation motif (ITAM) on the beta and gamma 
chains are phosphorylated by the Src family kinase Lyn. The phosphorylated ITAMs then 
act as docking sites to recruit spleen tyrosine kinase (Syk). When Syk binds to the 
activated ITAMs on FcεRI it undergoes a change in conformation that results in an 
increase in its enzymatic activity. Activated Syk is then autophosphorylated and serves to 
phosphorylate the adapter proteins LAT, which subsequently activate the PI3K pathway. 
These receptor-proximal signaling events also result in the activation of GTPases like Ras 
and Rho, leading to the stimulation of the ERK, JNK, and p38 MAPK pathways. 
Ultimately, the resulting increase in intracellular calcium leads to the degranulation 
process in which the pre-formed mediator-laden granules are released from the cell. PKC 
and MAPK activation also leads to stimulation of cPLA2, which liberates arachidonic 
acid from the plasma membrane and induces the mechanism responsible for eicosanoid 
production. Finally, de-novo protein production is initiated by activated transcription 
factors like NFAT and NFκB proteins that translocate into the nucleus (20).  
The complement of chemical mediators produced by mast cells differs from 
species to species, and even among subtypes within the same species. Generally 
contained within the granules are pre-formed compounds like vasomodulatory histamine 
and heparin, but also enzymes like tryptase, chymase, beta hexosamindase, and cathepsin 
4 
G (21).  Eicosanoids like prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) are 
synthesized by repurposing plasma membrane components (22). Cytokines, chemokines, 
and growth factors including TNFα, IL-6, IL-8, VEGF, GM-CSF, and MCP-1 are 
manufactured de-novo when required (23). Together, the chemical mediators induced by 
FcεRI XL work to induce the classical symptoms of allergy including increased mucous 
production, bronchoconstriction, and vasodilation leading to edema and erythema.  
 It is important to note that mature mast cells express not only c-kit and FcεRI, but 
also express a wide array of receptors including those for pathogen-associated molecular 
patterns (PAMP), IgG, neuropeptides, complement factors, eicosanoids, and cytokines 
(19). For this reason, mast cells can be activated not only by allergic FcεRI XL, but also 
but non-allergic mechanisms. For example, degranulation can also be caused by 
chemicals like insect/reptile venoms, endogenous tissue proteases, and complement 
factors such as c3/5a (24–26). Accordingly, mast cell mediator release has been shown to 
be highly heterogeneous depending on the stimuli and engaged receptor (27). Some 
stimuli may trigger all three phases of mast cell mediator release, while others may only 
induce degranulation or cytokine production (28). Mast cell activation by FcεRI XL has 
been extensively studied, but it is only recently that scientists have begun to shift focus to 
the effects of non-antigen stimuli on mast cell function. Specifically, the effects of 
cytokine activation on in-situ-matured human mast cells have been poorly characterized 




1.2 MAST CELLS IN ALLERGIC DISEASE 
Allergic disease is characterized by the Centers for Disease Control and 
Prevention (CDC) as an overreaction of the immune system to substances that generally 
do not affect other individuals. The CDC estimates that nearly 20 million US adults have 
been diagnosed with allergic rhinitis in the past year, while about 25 million Americans 
suffer from asthma. Broadly, allergic disease includes conditions like asthma, allergic 
rhinitis, urticaria, sinusitis, and food allergies. These conditions can each be characterized 
by individual clinical presentations, but tend to share a common set of symptoms. Most 
allergic diseases display chronic inflammation of some sort, although the inflamed area 
differs from condition to condition and confers the complications unique to each disease 
(29). According to the Mayo Clinic, those that suffer from asthma typically have airway 
inflammation leading to bronchoconstriction, making normal breathing difficult. 
Conversely, urticaria, or hives, presents as a superficial skin rash that is sensitive to the 
touch and often causes physical discomfort.    
Due to the pervasiveness of inflammation in these conditions, mast cells have 
long been implicated in the pathogenesis of allergic disease due to their ability to produce 
robust amounts of pro-inflammatory mediators. Additionally, it is known that mast cell 
numbers are increased in patients with active asthma or allergic rhinitis (5, 30). Several 
mast cell mediators have been shown to be causative in effecting the symptoms 
characteristic of allergic disease (31). When released, histamine causes powerful 
bronchoconstriction and vasodilation while the serine neutral proteases chymase and 
tryptase trigger local tissue remodeling (32). Additionally, the production of cytokines 
and chemokines cause recruitment and infiltration of immune cells, which leads to the 
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perpetuation rather than resolution of inflammation (19). Finally, the arachidonic acid-
derived eicosanoids released by mast cells contribute to bronchoconstriction and 
vasodilation as well as more recently elucidated mechanisms including effector cell 
trafficking, antigen presentation, immune cell activation, matrix deposition, and fibrosis 
(33). Human mast cells are known to biosynthesize and secrete PGD2 and LTC4, while 
murine mast cells are known to produce PGD2, thromboxane B2, and leukotriene B4 (34, 
35).    
Recently, the eicosanoid PGD2 been chiefly implicated in the pathogenesis and 
development of asthma. PGD2 is produced by the liberation of arachidonic acid (AA) 
from the plasma membrane by cytosolic phospholipase A2 (cPLA2) in response to 
increased intracellular calcium levels caused by inflammatory stimuli. Following 
membrane liberation, AA is converted into prostaglandin G2 (PGG2) and subsequently 
prostaglandin H2 (PGH2) by either constitutive cyclooxygenase-1 (COX-1) or inducible 
cyclooxygenase-2 (COX-2). Hematopoietic prostaglandin synthase (hPGDS) then 
metabolizes PGH2 into PGD2 which is released into the extracellular environment 
(hPGDS is expressed in hematopoietic immune cells, while lPGDS is expressed in brain, 
heart, and adipose tissue). Interestingly, PGD2 is rapidly metabolized once released into 
the blood stream, so any effects of the eicosanoid must take place near the cell of origin 
(36). Currently, two major PGD2 receptors have been identified: D prostanoid receptor-1 
(DP1) and chemoattractant receptor homologous molecule expressed on Th2 cells/D 
prostanoid receptor-2 (CRTH2/DP2). Depending on the receptor stimulated on the target 
cell, these effects can include immune cell activation and extravasation, vasodilation, and 
bronchoconstriction (37, 38). Together, these symptoms represent the classic clinical 
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presentation of allergic inflammation. PGD2 is produced by multiple cell types including 
those of the heart, brain, and immune system, but it is chiefly recognized as a product of 
mast cells. Due to the implication of both mast cells and PGD2 in allergic disease, 
therapeutic modulation or blocking of the arachidonic acid pathway in mast cells 
represents an important mechanism for understanding and treating allergic disease. 
1.3 PROSTAGLANDIN D2 IN ASTHMA PATHOGENESIS 
Several studies have pointed towards the importance of PGD2 during the 
pathogenesis and persistence of asthma (37–40). This cascade begins when an antigen 
presenting cell such as a dendritic cell or macrophage in the airway captures, processes, 
and presents antigen to a CD4+ T cell. The T cell is then polarized, generally into a Th2 
phenotype, which subsequently releases Th2 cytokines including IL-4, IL-5, and IL-13. 
These cytokines lead to eosinophilia, differentiation and proliferation of Th2 cells, airway 
hyper responsiveness (AHR), increased mucous production, and class switching in B 
cells to produce IgE. This increased IgE binds to the high-affinity IgE receptors FcεRI on 
the surface of mast cells, where it allows them to respond to the offending antigen. Once 
crosslinked, aggregated FcεRI induces the production and release of inflammatory 
mediators including PGD2 (38). Specifically during asthma, allergen challenge induces a 
swift and robust production of PGD2, which can culminate in levels about 150-fold 
higher than during pre-challenge (38). Notably, it is known that other cell types are 
capable of producing PGD2 including dendritic cells and Th2 cells, and it is suspected 
that others such as fibroblasts and other airway cells may be involved (38). However, 
data from several studies supports the notion that airway mast cells are in fact the main 
source of PGD2 during allergic inflammation (22, 38). Together, this data suggests that 
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mast cells and their production of PGD2 may link the acute and chronic effects of the 
allergic response by initiating the processes leading to the persistence of pulmonary 
inflammation.  
This theory was tested in several studies by either knocking out or interfering with 
DP1/2s ability to bind PGD2 and exert its functional effects. Loss of DP1 in a model of 
OVA-induced allergic inflammation led to reductions in Th2 cytokine levels, mucous-
containing cells, as well as lymphocyte and eosinophil infiltration in BALF and lung 
tissue compared to controls (37). Another similar experiment examined the effects of 
using a DP2 antagonist to inhibit asthma-like pathological changes, resulting in the 
conclusion that like DP1, DP2 plays a critical role in allergic inflammation (37). 
1.4 RESVERATROL AND MAST CELL FUNCTION 
Resveratrol is a natural polyphenol found in dark berries, particularly the skin of 
red grapes, and red wine. Under natural conditions, plants produce Resveratrol to help 
fight off microbial infection in addition to using it to survive periods of inadequate water 
and nutrient supply (41). This stilbenoid has been the subject of many recent studies due 
to its reported protective effects against cardiovascular disease, inflammation, cancer, and 
aging (42–45). As a direct effect of these reports, Resveratrol is viewed in the general 
community as a “magic bullet” that provides numerous unfounded health benefits. 
Additionally, the recent resurgence in demand for naturally derived medications has 
made Resveratrol a popular nutritional supplement and ingredient in over-the-counter 
topical lotions. Most importantly, Resveratrol has demonstrated a plethora of biological 
activities both in-vitro and in-vivo such as reduction of cyclooxygenase expression, 
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modulation of NFκB activity, and stimulation of cytokine production in CD4+ and CD8+ 
T cells (46). When taken together, this information suggests a role for Resveratrol in 
modulating the greater immune system as a whole.   
Since Resveratrol has been shown to have a strong anti-inflammatory effect, it 
follows that many researches have been interested in investigating its action on mast cell 
function. In fact, there are numerous papers that outline how Resveratrol modulates mast 
cell function and mediator production. Resveratrol was shown to dose-dependently 
decrease histamine and beta-hex release in rat RBL-2H3 mast cells by attenuating Syk, 
PLCγ, and PKC activation. Additionally, in a mouse model of anaphylaxis, Resveratrol 
inhibited IgE-mediated degranulation and subsequent histamine release (47). Han et al. 
(2015) also reported that Resveratrol attenuated Th2 and TNFα cytokine production in rat 
RBL-2H3 mast cells by diminishing phosphorylation of p38, MAPK, ERK, and JNK 
caused by FcεRI XL. In a mouse model of asthma, Resveratrol was shown to have 
therapeutic effects by decreasing TNFα levels in the bronchoalveolar lavage fluid 
(BALF), fibrosis in the airway, and Syk phosphorylation and degranulation in mast cells 
(48). In a related model of allergic disease Resveratrol showed protective effects by 
inhibiting the formation of atopic-dermatis (AD)-like skin lesions through suppression of 
the HMGB1 inflammatory pathway(49). Experiments performed with BMMCs 
demonstrated that Resveratrol may be able to suppress IgE-mediated PGD2 production 
(50). Finally, research on Resveratrol’s effects on the human mast cell line HMC-1 
revealed its ability to attenuate pro-inflammatory cytokine production, COX-2 
expression, and ERK and NFκB activation (51). Taken together, these studies strongly 
suggest that Resveratrol attenuates mast cell pro-inflammatory mediator production by 
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suppressing the activation of kinases and transcription factors important during FcεRI XL 
signaling.  
While the data produced in these studies is promising, there is a failure to address 
the biological action of Resveratrol on mature in-situ-derived human mast cells. Due to 
its inclusion in topical lotions, the effect of Resveratrol on human skin mast cells is 
particularly important, as this cell population would be readily exposed to Resveratrol 
through superficial application.   
1.5 IL-6 SIGNALING 
IL-6 is a pleiotropic cytokine that is ubiquitously associated with inflammation 
(52). Produced in response to infection, tissue damage, or inflammation, IL-6 generated 
and released by nearly all immune cells and most stromal cells (53). The IL-6 receptor 
complex is composed of two vital parts: the ligand binding portion IL-6Rα and the signal 
transducing subunit gp130. IL-6 belongs to a family of several gp130-utilitzing cytokines 
including leukemia inhibitory factor (LIF), oncostatin M (OSM), IL-11, ciliary 
neurotrophic factor (CNTF), and others (54). Signaling can occur via two different 
mechanisms, classical signaling and trans-signaling. Classical signaling involes both 
membrane-bound IL-6Rα and gp130, whereas trans-signaling utilizes soluble IL-6Rα 
binding to membrane-gp130 (55). The trans-signaling mechanism effectively works to 
expand the number of cell types that can respond to IL-6 signaling due to the selective 
expression of IL-6Rα on immune cells and near ubiquitous expression of gp130 on most 
cell types (56). IL-6 binding leads to receptor dimerization which activates the associated 
Janus Kinases (Jaks). These Jaks autophosphorylate themselves as well as gp130, and 
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signal transducer and activator of transcription-3 (STAT-3) will then bind to these 
phosphorylation sites and become phosphorylated themselves by Jak. Activated STAT3 
then dimerizes and translocates to the nucleus where it regulates transcription of IL-6 
responsive genes including suppressor of cytokine signaling-3 (SOCS-3). SOCS-3 works 
as a negative feedback mechanism and subsequently inhibits IL-6 signaling by blocking 
Jak activation (57). In addition to the Jak/STAT pathway, ligation of the IL-6 receptor 
leads to activation of the PI3K/Akt (58) and Ras/Raf/MAPK (59) pathways. Depending 
on the target cell, these signals cooperate to regulate processes like B cell antibody 
production, T cell differentiation, hematopoiesis, and the acute phase reaction (52). Due 
to its ability to influence such a wide range of activities during inflammation, increased 
IL-6 levels are associated with many diseases and pathologies in which chronic 
inflammation is a hallmark (54, 60, 61).  In humans, IL-6 levels are correlated with 
severity or pathogenesis of allergic diseases including asthma (62–65), urticaria (66, 67), 
and mastocytosis (68, 69) in which mast cells play a key role. The exact role of IL-6 in 
allergic disease is not known, but there is precedence for modulation of mast cell 
development, survival, proliferation, adhesion, and chemokinesis (3, 70–72). Recently, it 
was shown that IL-6 enhanced mast cell proliferation, maturation, and reactivity 
following FcεRI XL by suppressing the expression of feedback inhibitor SOCS-3 (73). 
1.6 ANGIOGENESIS 
Angiogenesis is defined as the formation of new vessels from pre-existing ones, 
and serves vital physiological and pathological purposes. Vessel formation is critical 
during embryonic development and persists throughout an individual’s life where it can 
be central to processes like wound healing and pregnancy in females (74–76). 
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Conversely, angiogenesis plays a central role in tumor formation and persistence while 
also contributing to inflammatory disease (77, 78). 
Angiogenesis is generally initiated in response to stress in the local tissue, which 
typically manifests as hypoxia (79). This hypoxic environment can be a result of one or 
several factors including physiological growth and development, mechanical disruption 
such as surgery, or disease. Regardless, in each case these conditions lead to the 
upregulation and release of the chemical mediators responsible for new vessel growth 
(80). Generally, hypoxia will trigger the expression of proteases and the transcription 
factor hypoxia-inducible factor 1 (HIF-1) which is considered to be the master regulator 
of the cellular response to hypoxia (81). HIF-1 will then induce the expression and 
subsequent release of pro-angiogenic factors including VEGF and FGF (80). The released 
proteases will work to degrade the basement membrane which also results in pericyte 
detachment. Released VEGF and other growth factors then bind to the receptors on the 
surface of endothelial cells (EC), resulting in the proliferation and migration of ECs along 
the factor gradient. As the new vessel branch grows outward, circulating endothelial 
progenitor cells will adhere to the area of angiogenesis and participate in new vessel 
formation. Angiogenesis is terminated via a negative regulation mechanism in which 
VEGF induces delta-like ligand (DLL) 4, which binds to Notch-1 and decreases VEGF 
receptor (VEGFR) expression (82). The resulting decrease in VEGFR expression halts 
EC proliferation and stops growth of the new vessel. Finally, the local tissue begins to 
secrete platelet derived growth factor (PGDF) which binds to its receptors on the ECs and 
reduces proliferation and VEGF sensitivity and triggers the attachment of pericytes along 
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the external surface of the new vessel. With a newfound blood supply, the local tissue can 
now function normally, or in the case of tumors, continue uncontrolled growth (83, 84).         
Because the formation of new vessels requires the cooperation of many different 
cell types, this complex process is regulated by a slew of molecular signals. In fact, 
several dozen angiogenesis-associated factors have been isolated and identified thus far 
including growth factors, cytokines, and various enzymes (85). These factors are 
comprised of both positive and negative regulators of angiogenesis, and their balance is 
linked to the shift from physiological to pathological vessel growth. 
Understanding how angiogenesis is regulated represents a very important 
objective for effective clinical translation. When considering medical intervention in 
angiogenesis there are two scenarios: one in which initiation of therapeutic angiogenesis 
can alleviate or repair the effects of tissue damage, and one where inhibiting pathological 
angiogenesis can resolve or mitigate its progression (86). Comprehending the role mast 
cells play in both of these situations is critical in effectively targeting them to treat human 
disease in which controlling new vessel growth is pivotal.  
1.7 MAST CELLS IN ANGIOGENESIS 
Immune cell contribution towards angiogenesis is not a novel idea, and recent 
data suggests that vessel growth and inflammation are dependent on one another, rather 
than being mutually exclusive. During inflammation, local immune cells secrete 
angiogenic factors that lead to the formation of new vessels. These new vessels lead to 
the perpetuation of inflammation by providing new highways for immune cell trafficking 
and extravasation into the local tissue. This cyclical pathway provides the mechanism for 
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persistent inflammation that characterizes many chronic inflammatory diseases like 
rheumatoid arthritis (78, 87). It is known that mast cells tend to accumulate and localize 
around tumor sites (1). However, the stimuli for their migration and the function they 
perform once resident in the tumor microenvironment (TME) is still contested. Although,  
increased concentration of SCF in the TME may provide a clue as to what factor is 
recruiting MCp from circulation (88). One theory for their heavy presence in the TME is 
the ability of mast cells to produce and release powerful angiogenesis-associated factors. 
New vessel formation is vital to tumor growth as the cancer requires increased circulation 
to remove waste and provide nutrients as it expands. Additionally, it is accepted that mast 
cells can contribute to tissue homeostasis by regulating remodeling, repair, and fibrosis 
(89). Thus, a role for mast cells in both developmental and pathological angiogenesis is 
supported by the current literature. 
Mast cells of different species and phenotypes have been shown to produce FGF-
2, VEGF-A-D, tryptase, chymase, histamine, heparin, IL-8, TNFα, TGF-β, NGF, uPA, 
and matrix metalloproteases (MMP) and their inhibitors (90, 91). All of these compounds 
are involved either directly in angiogenesis, or function in the degradation of the 
extracellular matrix (ECM) which allows for the formation of new vasculature. In fact, it 
has been directly shown that mast cells are potent activators of angiogenesis by using the 
chick embryo chorioallantoic membrane (CAM) assay (92). The CAM assay is an 
established model for studying neovascularization and allows the researcher to directly 
visualize vessel growth. Mast cell-stimulated angiogenesis has also been documented in 
many studies utilizing both in-vivo and ex-vivo systems (93–96). Additionally, the 
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observation that mast cells are frequently found in close proximity to blood vessels 
suggests a role for mast cells in angiogenesis (97).  
The studies described here identify novel roles for IL-6 and Resveratrol in the 
regulation of mediator release from in-situ-matured mast cells from human ski
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CHAPTER 2 
MATERIALS AND METHODS- RESVERATROL PREFERENTIALLY 
INHIBITS IGE-DEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES 
TNF PRODUCTION FROM HUMAN SKIN MAST CELLS
1 
Resveratrol is a natural polyphenol found in the skin of red grapes, dark berries, 
and peanuts. This stilbenoid has been reported to have many positive health benefits, 
including as an antioxidant, anti-aging, and anti-inflammatory compound. Due to its anti-
inflammatory reputation, many recent studies have examined its direct effects on immune 
cells including mast cells. However, never before have the effects of Resveratrol on in-
situ-matured humans skin mast cells been examined. The methods detailed in this section 
were designed to assess the toxicity of Resveratrol on human skin mast cells, in addition 
to its effects on degranulation, cytokine production, gene expression, and eicosanoid 
biosynthesis. Studies were performed on in-situ-matured human skin mast cells that were 
isolated in accordance with the University of South Carolina Internal Review Board 
(IRB).  
2.1 ISOLATION AND PURIFICATION OF HUMAN SKIN MAST CELLS 
Human skin mast cells were isolated and purified from fresh surgical specimens 
of human skin tissue obtained from the Cooperative Human Tissue Network of the 
National Cancer Institute, as approved by the human studies Internal Review Board at 
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 Parts of this section have been excerpted from the following research article: 
Shirley, D., C. McHale, and G. Gomez. 2016. Resveratrol preferentially inhibits IgE-dependent 
PGD2 biosynthesis but enhances TNF production from human skin mast cells. Biochim. Biophys. 
Acta - Gen. Subj. 1860. 
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University of South Carolina. The tissues were mechanically disrupted with 
surgical scissors and then digested 3 × 1 h at 37 °C with collagenase type II (Worthington 
Biochemical, Lakewood, NJ), hyaluronidase from bovine testes, and DNase I (Sigma-
Aldrich, St. Louis, MO) in HBSS wash buffer (1X HBSS, 0.04% NaHCO3, 1% fetal 
bovine serum, 1% HEPES, 0.1% CaCl2) containing amphotericin B and 
antibiotic/antimycotic solution. After each digestion period, the samples were filtered 
through 40 μm nylon cell strainers. The filtered cells were collected by centrifugation, 
washed and re-suspended with wash buffer. After the final digestion, the collected cells 
were separated on Percoll by density centrifugation. The cells at the interface of buffer 
and Percoll layers were collected, washed and re-suspended at 5 × 10
5
 cells/ml in serum-
free X-VIVO 15™ media (Lonza, Walkersville, MD) containing recombinant human 
stem cell factor (SCF, 100 ng/ml) (PeproTech, Rocky Hill, NJ). The cells were 
transferred onto 24-well plates and maintained under standard culture conditions (37 °C, 
5% CO2) with weekly media changes. Purity was assessed cytochemically by 
metachromatic staining with acidic toluidine blue. Greater than 95% purity was achieved 
by 6 weeks of culture, and the mast cells were used in experiments after 8 weeks. A 
schematic of this process is shown in Figure 2.1. 
 2.2 VIABILITY ASSAY 
Mast cell viability was determined by MTT reduction assay using the 
TACS
®
 MTT Cell Proliferation Assay from Trevigen (Gaithersburg, MD) according to 
the manufacturer’s instructions. Briefly, human skin mast cells were plated in triplicate at 
10
5
cells/well of a 96-well plate in 100 µl X-VIVO media + SCF. Resveratrol or DMSO 
was added, and the cells were incubated for 24, 48, or 72 h under normal culture 
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conditions (37°C, 5% CO2). MTT Reagent was added to the cells and incubated for an 
additional 4 h. Detergent was added and the plate was incubated overnight at room 
temperature. Absorbance values at 570 nm were acquired with a BioTek Synergy HT 
microplate reader (BioTek, Winooski, VT). 
2.3 MAST CELL ACTIVATION 
Sensitized human skin mast cells (10
6
/ml) were activated by crosslinking FcεRI 
with the hapten 4-hydroxy-3-nitrophenylacetyl conjugated to bovine serum albumin at a 
16:1 molar ratio (NP-BSA; Biosearch Technologies, Novato, CA) at 37 °C. For 
sensitization, 10
6
 cells/ml were incubated in X-VIVO 15™ media or Tyrode's buffer 
(135 mM NaCl, 1 mM MgCl2, 20 mM Hepes, 5 mM KCl, 1.8 mM CaCl2, 5.6 mM 
glucose; pH 7.4, 0.05% bovine serum albumin) containing 1 μg/ml chimeric human anti-
NP IgE (human Fc + mouse Fab) (clone JW8/1; AbD Serotec, Raleigh, NC) for 3 h at 
37 °C. After washing to remove unbound IgE, the mast cells were re-suspended at 
10
6
 cells/ml in X-VIVO 15™ media or Tyrode's buffer, pre-treated with Resveratrol 
(Sigma-Aldrich, St. Louis, MO) or DMSO (vehicle) for 1 h at 37 °C, and then activated 
with 100 ng/ml NP-BSA for the indicated amount of time. 
2.4 β-HEXOSAMINIDASE AND PGD2 ASSAYS 
Human skin mast cells were activated with 100 ng/ml NP-BSA for 30 min at 
37 °C in Tyrode's buffer. After the incubation period, the mast cells and buffer were 
separated by centrifugation (2000 rpm × 5 min) in an Eppendorf 5424 centrifuge, and the 
pelleted cells were lysed with an equal volume of 1% Triton X-100. β-Hexosaminidase 
activity in supernatant and cell lysate was assayed by measuring the release of p-
nitrophenol from substrate p-nitrophenyl N-acetyl-β-D-glucosaminide (pNAG; Sigma-
19 
Aldrich, St. Louis, MO) as described (98, 99). In a 96-well plate, 5 μl of supernatant or 
lysate were mixed with 45 μl of 4 mM p-nitrophenyl N-acetyl-β-D-glucosaminide 
(pNAG) in citric acid buffer (pH 4.5) and incubated for 1 h at 37 °C. The reaction was 
stopped by adding 150 μl of 0.2 M glycine, pH 10.7. Absorbance values at 405 nm were 
acquired with a BioTek Synergy HT microplate reader (BioTek, Winooski, VT). Percent 
degranulation was calculated as percent release of β-hexosaminidase using the formula: 
% β-hex release = ((supernatant) / (supernatant + lysate)) × 100. PGD2 in the supernatant 
was measured with a commercial enzyme immunoassay kit (Cayman Chemical, Ann 
Arbor, MI) according to the manufacturer's instructions. 
2.5 CYTOKINE ELISA 
Sensitized human skin mast cells were activated with 100 ng/ml NP-BSA for 3 h 
at 37 °C in X-VIVO 15™ media containing SCF and 100 μg/ml soybean trypsin inhibitor 
(SBTI; Sigma-Aldrich, St. Louis, MO). After the activation period, the mast cells and 
media were separated by centrifugation (2000 rpm × 5 min). IL-6 or TNF in supernatant 
was quantified by enzyme-linked immunosorbent assay (ELISA) in a 384-well format as 
described (100). Capture (purified) and detection (biotinylated) rat antibodies (BD 
Biosciences) used were: IL-6 (MQ2-13A5 and MQ2-39C3), TNF (MAb1 and MAb11). 
Serially diluted recombinant cytokine standards (BD Biosciences, San Jose, CA) were 
used to generate standard curves. After developing with the substrate for peroxidase 2,2′-
azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma-Aldrich, St. Louis, MO), 
absorbance values at 405 nm were obtained and cytokine concentrations in experimental 
samples determined with a BioTek Synergy HT microplate reader (BioTek, Winooski, 
VT) and Gen5 Data Analysis Software. 
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2.6 QUANTITATIVE REAL TIME PCR 
Cytokine and COX gene expression was determined from sensitized human skin 
mast cells activated with 100 ng/ml NP-BSA for 3 h or 30 min, respectively. RNA was 
isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized from 
350 ng total RNA with the SuperScript™ III First-Strand Synthesis System (Life 
Technologies, Grand Island, NY). The kits were used according to the manufacturer’s 
instructions. The PCR reaction mix was composed of 2 µl of cDNA, 1 µl each of sense 
and antisense primers (10 µM each) and 12.5 µl of iQ SYBR
®
 Green Supermix (Bio-Rad, 
Hercules, CA) in a final volume of 25 µl. A hot-start PCR protocol (95°C × 5 min, (95°C 
× 30 sec, 55°C × 30 sec, 72°C × 30 sec) × 35 cycles, 95°C × 1 min, 55°C × 1 min) was 
performed on a CFX Connect Real Time PCR Detection System (Bio-Rad, Hercules, 
CA). Fold change in expression was determined by the 2
ΔΔCt
 method. The oligonucleotide 
primers (5’-3’; forward and reverse) used are shown in Table 2.1. 
2.7 WESTERN BLOTTING 
Whole cell lysates were prepared from sensitized human skin mast cells 
(10
6
/sample) that were activated with 100 ng/ml NP-BSA for 5 min at 37°C. Protein 
equivalents of 5×10
5
 cells/lane were separated by reducing SDS-PAGE and transferred 
onto nitrocellulose membranes. Two-color staining for Akt, p38 and p42/44 was 
performed using Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE), and Syk 
immunoblotting was performed with 5% non-fat dry milk in 25 mM Tris, pH7.4, 0.15 M 
NaCl, 0.1% Tween-20 (TNT buffer) as previously described (101). The primary 
antibodies used were: rabbit polyclonal anti-p38 MAPK, mouse monoclonal anti-
phospho-p38 MAPK (Thr180/Tyr182)(28B10), rabbit polyclonal anti-p44/42 (Erk 1/2), 
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mouse monoclonal anti-phospho-p42/44 (Erk1/2) (E10), rabbit polyclonal anti-Akt, 
mouse monoclonal anti-Akt (Thr308)(L32A4), rabbit polyclonal antibody against total 
Syk (Cell Signaling Technology, Danvers, MA), and mouse monoclonal antibody against 
human phospho-Syk (Tyr525) (R&D Systems, Minneapolis, MN). The secondary 
antibodies used were goat anti-rabbit IRDye 680RD and goat anti-mouse 800CW (LI-
COR Biosciences, Lincoln, NE). The blots were scanned on an Odyssey
®
 CLx Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE). 
Table 2.1: Primer sequences for qRT-PCR 
Gene Sequence 
IL-6 F: AGTGAGGAACAAGCCAGAGC   
R: AAAGCTGCGCAGAATGAGAT 
TNFa F: GACAAGCCTGTAGCCCATGT  
R: TTATCTCTCAGCTCCACGCC 
COX-1 F: TCTTGCTGTTCCTGCTCCTG  
R: GTTGGAGCGCACTGTGAGTA 
COX-2 F: ACTGCTCAACACCGGAATTT  
R: CAAGGGAGTCGGGCAATCAT 
GAPDH F: CAATGACCCCTTCATTGACC  
R: TTGATTTTGGAGGGATCTCG 
 
2.8 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism version 6.0c for Mac OS 











RESULTS- RESVERATROL PREFERENTIALLY INHIBITS IGE-
DEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES TNF 
PRODUCTION FROM HUMAN SKIN MAST CELLS
2
 
3.1 EFFECT OF RESVERATROL ON VIABILITY OF HUMAN SKIN MAST 
CELLS 
To begin our studies, we sought to determine the effect of Resveratrol on viability 
of human skin mast cells. Mast cells were cultured without or with 1, 10 or 100 μM 
Resveratrol or DMSO for up to 72 h under normal culture conditions (37 °C, 5% CO2). 
Cell viability was determined by MTT assay at each 24 h interval (Fig. 3.1). No 
significant loss of viability was observed. In fact, a very slight but statistically significant 
increase in cell viability was observed with Resveratrol at 10 μM for 24 h or 100 μM for 
72 h compared with vehicle control. Thus, Resveratrol did not induce cell death. 
3.2 PGD2 BIOSYNTHESIS IS MORE SENSITIVE THAN DEGRANULATION TO 
INHIBITION BY RESVERATROL 
To determine the effect of Resveratrol on degranulation, human skin mast cells 
were sensitized with anti-NP IgE, pre-treated with a dose range of Resveratrol for 1 h 
then challenged for 30 min with 100 ng/ml NP-BSA. Degranulation was determined by 
β-hexosaminidase release assay. As shown in Fig. 3.2A, Resveratrol dose-dependently 
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inhibited FcεRI-induced degranulation. Mean percent degranulation ± SEM of 
control skin mast cells activated without Resveratrol was 48.5 ± 1.9% whereas that of 
mast cells pre-treated with Resveratrol at the indicated concentration was: 55 ± 3% (3 
μM), 52 ± 6% (6 μM), 44 ± 9% (12.5 μM), 36 ± 17% (25 μM), 20 ± 12% (50 μM) and 
10.5 ± 6% (100 μM). However, significant inhibition occurred only in mast cell pre-
treated with Resveratrol at 50 μM (p b 0.05) and 100 μM (p b 0.0001). Thus, FcεRI-
induced degranulation of human skin mast cells is resistant to inhibition with Resveratrol 
at concentrations below 50 μM, but significantly inhibited with higher concentrations. 
Next, we determined the effect of Resveratrol on PGD2 production. IgE-sensitized skin 
mast cells were pre-treated with a dose range of Resveratrol for 1 h and then challenged 
for 30 min with 100 ng/ml NP-BSA. PGD2 in the supernatant was measured with 
commercial enzyme immunoassay kit. The data showed a strong inhibitory effect of 
Resveratrol on PGD2 biosynthesis with significant inhibition achieved at all 
concentrations tested (Fig. 3.2B). Mast cells activated without Resveratrol pretreatment 
produced 27,867 ± 9099 pg/ml PGD2 whereas those pretreated with the indicated amount 
of Resveratrol produced the following amount: 9306 ± 2276 pg/ml (3 μM), 5325 ± 1867 
pg/ml (6 μM), 2350 ± 914 pg/ml (12.5 μM), 1165 ± 676 pg/ml (25 μM), 291 ± 259 pg/ml 
(50 μM), and 31 ± 14 pg/ml (100 μM). Thus, FcεRI-induced PGD2 biosynthesis is highly 
sensitive to inhibition by Resveratrol. 
3.3 RESVERATROL AUGMENTS FCεRI-INDUCED TNF PRODUCTION FROM 
HUMAN SKIN MAST CELLS 
To evaluate the ability of Resveratrol to regulate pro-inflammatory cytokine 
production, IgE-sensitized human skin mast cells were pretreated with 10 or 100 μM 
Resveratrol or DMSO for 1 h, and then challenged for 3 h with 100 ng/ml NP-BSA. 
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Secreted IL-6 and TNF was measured using ELISA, and cytokine gene expression was 
determined by quantitative RT-PCR. Surprisingly, TNF production from mast cells 
pretreated with 10 μM Resveratrol was significantly increased compared to that secreted 
from untreated mast cells (Fig. 3.3A). Net TNF produced by control mast cells was 104 ± 
31 pg/106 cells whereas mast cells pre-treated with 10 μM Resveratrol produced 279 ± 
66 pg/106 cells. In accordance with increased TNF secretion, FcεRI-induced expression 
of TNF mRNA in Resveratrol-treated mast cells was increased 2-fold compared to non-
treated activated mast cells: 5 ± 1 fold increase (non-treated) versus 10 ± 2 fold increase 
(Resveratrol treated) (Fig. 3.3B). In contrast, IL-6 production was not significantly 
affected by 10 μM Resveratrol although some inhibition was apparent (Fig. 3.3C and D). 
Thus, the enhancing effect of 10 μM Resveratrol on TNF did not extend to IL-6. At 100 
μM, Resveratrol strongly inhibited IL-6 production and secretion (Fig. 3.3C and D), but 
did not significantly affect TNF (Fig. 3.3A and B). In time course experiments, 10 μM 
Resveratrol enhanced FcεRI-induced TNF production at 3, 6 and 24 h (Fig. 3.3F), 
whereas IL-6 was inhibited at 24 h (Fig. 3.3G).We also measured β-hexosaminidase 
activity in the sample supernatants to show that 10 μM Resveratrol had no effect on 
degranulation even with prolonged exposure, whereas 100 μM Resveratrol completely 
inhibited degranulation (Fig. 3.3E). Thus, confirming our earlier finding (Fig. 3.2A). 
These data reveal a previously unrecognized ability of Resveratrol at low concentration to 
enhance FcεRI-induced TNF production from human skin mast cells. 
3.4 RESVERATROL INHIBITS IGE-DEPENDENT COX-2 INDUCTION BUT 
NOT SYK PHOSPHORYLATION 
The finding that PGD2 biosynthesis was inhibited by Resveratrol at concentrations 
that did not affect degranulation (Fig. 3.2) suggested that Resveratrol at relatively low 
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concentrations preferentially inhibited the eicosanoid pathway downstream of FcεRI-
proximal signaling events. To determine if this was the case, we first investigated the 
effect of Resveratrol on expression of the cyclooxygenases COX-1 and COX-2, key 
enzymes involved in the conversion of arachidonic acid to prostaglandins (34, 102). Both 
COX-1 and COX-2 are involved in PGD2 biosynthesis. However, whereas COX-1 is 
constitutively expressed in mast cells, COX-2 expression is an inducible event following 
FcεRI stimulation. In fact, COX-2 is the only major enzyme involved in eicosanoid 
production whose expression is induced in mast cells following FcεRI crosslinking; thus, 
making it an ideal candidate target for Resveratrol. To this end, IgE-sensitized skin mast 
cells were pre-treated with 1, 10 or 100 μM Resveratrol or DMSO for 1 h, and then 
challenged for 30 min with 100 ng/ml NP-BSA. Total RNA was isolated, and COX-1 and 
COX-2 expression was assessed by real time PCR. As expected, COX-1 expression was 
not affected whereas COX-2 expression was significantly increased after FcεRI 
crosslinking. Moreover, pre-treatment with Resveratrol had no effect on the constitutive 
expression of COX-1 (Fig. 3.4A), whereas IgE-dependent COX-2 expression was 
significantly inhibited in skin mast cells pre-treated with 10 μM (p b 0.05) or 100 μM 
Resveratrol (p b 0.01) (Fig. 3.4B). The fold increase ± SEM in COX-2 expression in 
FcεRI-activated control mast cells was 29 ± 5, and 36 ± 5, 17 ± 4, or 1 ± 0.2, 
respectively, in mast cells pre-treated with 1, 10 or 100 μM Resveratrol. Interestingly, 
COX-2 expression appeared to be slightly increased in skin mast cells pre-treated with 1 
μM Resveratrol although the difference was not statistically significant (p = 0.2). Thus, 
FcεRI induced COX-2 expression was significantly inhibited by Resveratrol. Our finding 
that high concentrations of Resveratrol were required to inhibit degranulation indicated 
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that FcεRI-induced signals occurred normally with Resveratrol at low concentrations. To 
confirm this, we analyzed the effect of Resveratrol on Syk activation since degranulation 
is dependent on Syk activation (103–105). Upon FcεRI crosslinking, Syk is rapidly 
recruited to ITAM residues on FcεRI γ chains where it is phosphorylated to propagate the 
cascade of signaling events (106). Therefore, we analyzed the phosphorylation status of 
Syk at the activating tyrosine residue Y525 by SDS-PAGE and Western blotting. Whole 
cell lysates were prepared from IgE-sensitized human skin mast cells that had been 
pretreated with 1, 10 or 100 μM Resveratrol or DMSO for 1 h and then activated for 5 
min with 100 ng/ml NP-BSA. As expected, phosphorylated Syk was clearly detected in 
lysates from FcεRI-activated mast cells, but not in non-activated mast cells. Further, 
FcεRI-induced Syk phosphorylation was not affected in skin mast cells pre-treated with 1 
or 10 μM Resveratrol (Fig. 3.5) in accordance with the observation that Resveratrol at 
these concentrations did not affect degranulation (Fig. 3.2A), which is dependent on Syk 
activation (104). Interestingly, Resveratrol at 100 μM, a concentration that completely 
inhibited degranulation (Fig. 3.2A), also did not significantly inhibit FcεRI-induced Syk 
phosphorylation (17 ± 5% versus 28 ± 6% in control cells; p = 0.2) although an inhibitory 
trend was apparent. Thus, FcεRI-induced Syk phosphorylation was not inhibited with 
Resveratrol in human skin mast cells.  
3.5 INCREASED TNF PRODUCTION BY RESVERATROL IS NOT DUE TO 
INCREASED FCεRI-INDUCED ACTIVATION OF AKT, P38, OR P42/44 
To determine the effect of Resveratrol on downstream signaling processes, we 
analyzed the phosphorylation status of Akt, p38 and p42/44 (ERK1/2) following FcεRI 
cross-linking since these intermediate signaling molecules have been implicated in 
activation of various transcription factors and cytokine production by mast cells (107–
28 
109). To do so, SDS-PAGE and Western blotting were performed using whole cell 
lysates prepared from IgE-sensitized human skin mast cells that were pre-treated with 
Resveratrol at 1, 10 or 100 μM for 1 h, and challenged for 5 min with 100 ng/ml NP-
BSA. As demonstrated in Fig. 3.6, FcεRIinduced phosphorylation of Akt was minimally 
inhibited with 10 μM Resveratrol whereas p38 or p42/44 phosphorylation was not 
affected. In contrast, 100 μM Resveratrol completely inhibited the phosphorylation of 
these signaling molecules. These data indicate that the observed increase in TNF 
production from human skin mast cells pre-treated with 10 μM Resveratrol (Fig. 3.3) was 















Figure 3.1: Effect of Resveratrol on viability of human skin mast cells. Human skin mast 
cells were treated with 1, 10 or 100 μM Resveratrol or DMSO for 24, 48, or 72 h, and cell 
viability was determined by MTT reduction assay as described in Material and methods. 
Absorbance values at 570 nm correspond to cell viability. Bars represent the 
mean ± SEM (n = 3) of absorbance values obtained with mast cells isolated from normal 
skin tissue of different donors. *p < 0.05 by Student's t-test comparing absorbance values 

















Figure 3.2: Effect of Resveratrol on FcεRI-induced degranulation and PGD2 production 
from human skin mast cells. Dose-dependent effect of Resveratrol on Ag/IgE-induced 
degranulation (A) or PGD2 production (B) from human skin mast cells sensitized with 
chimeric human anti-NP IgE and challenged with 100 ng/ml NP-BSA. Percent 
degranulation was determined by β-hexosaminidase release assay. Calcium ionophore 
A23187 was used as a positive control for degranulation potential. Secreted PGD2 was 
measured by enzyme immunoassay. Data are expressed as the mean ± SEM of values 
obtained from independent experiments with mast cells from normal skin tissue of n = 3 
(A, degranulation) or n = 5 (B, PGD2) different donors. Values were compared to those 
obtained from mast cells that were activated without Resveratrol (NP-BSA only). 
Statistical significance was determined by one-way ANOVA followed by Dunnett's 
multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and 
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Figure 3.3: Effect of Resveratrol on FcεRI-induced production of TNF and IL-6 from 
human skin mast cells. Human skin mast cells sensitized with anti-NP IgE were pre-
treated with Resveratrol for 1 h and then challenged with antigen NP-BSA for 3 h (A–E), 
or 3, 6, or 24 h (F and G). Secreted cytokines in supernatant were measured by ELISA, 
and gene expression was assessed by quantitative RT-PCR. Fold change was determined 
by 2
ΔΔCt
 method comparing to expression in non-activated mast cells (y = 1, hatched 
line). Net secreted TNF (A, n = 6) or IL-6 (C, n = 5). Spontaneously released TNF was 
8 ± 4 pg/10
6
 cells, and IL-6 was 2 ± 2 pg/10
6
 cells. Fold change in TNF (B, n = 7) or IL-6 
(D, n = 7) gene expression. β-Hexosaminidase in media (E, n = 6). Time course 
evaluation for TNF (F, n = 3) or IL-6 (G, n = 3). Data shown is expressed as 
mean ± SEM of values from skin mast cells from different donor tissue in independent 
experiments. Statistical significance was determined by one-way ANOVA followed by 
Sidak's multiple comparisons test. *p < 0.5, ***p < 0.001, and 
#







Figure 3.4: Effect of Resveratrol on COX-1 and COX-2 expression in human skin mast 
cells. Expression analysis of COX-1 (A, n = 6) or COX-2 (B, n = 5) in FcεRI-activated 
humans was performed by qRT-PCR in independent experiments with mast cells from 
different donor tissue. Fold change, expressed as mean ± SEM, was determined by 
2
ΔΔCt
 method comparing to expression in non-activated mast cells (y = 1, hatched line). 
The data reflect the effect of Resveratrol on the constitutive expression of COX-1 and 
induction of COX-2. Statistical significance was determined by pairwise Student's t-test 
comparing to values from mast cells activated without Resveratrol pre-treatment. 









Figure 3.5: Effect of Resveratrol on FcεRI-induced phosphorylation of Syk in human skin 
mast cells. Phosphorylation of Syk (Y525) was determined by quantitative infrared 
Western blotting of whole cell lysates of sensitized mast cells pre-treated with 1, 10 or 
100 μM Resveratrol or DMSO (vehicle), and activated for 5 min with 100 ng/ml NP-
BSA. The blot shown (A) is representative of 3 independent experiments with mast cells 
from skin tissue of different donors. Percent phosphorylation expressed as mean ± SEM 
(B, n = 3) was determined as the ratio of phosphorylated Syk (Y525) to total Syk using 
fluorescent signal values obtained with an infrared imager. Statistical significance was 
determined by Student's t-test comparing to values from mast cells activated without 




















Figure 3.6:  Effect of Resveratrol on FcεRI-induced phosphorylation of Akt, p42/44 and 
p38 in human skin mast cells. Phosphorylation of Akt (A), p42/44 (B, upper panel) and 
p38 (B, lower panel) was determined by quantitative infrared Western blotting of whole 
cell lysates of sensitized mast cells pre-treated with 1, 10 or 100 μM Resveratrol or 
DMSO (vehicle), and activated for 5 min with 100 ng/ml NP-BSA. Fold induction of 
phosphorylation was determined from fluorescent signal values obtained with an infrared 
imager. The blots shown are representative of 3 independent experiments with mast cells 






CHAPTER 4  
DISCUSSION- RESVERATROL PREFERENTIALLY INHIBITS IGE-
DEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES TNF 




In this study, we investigated the effects of Resveratrol on IgE-dependent release 
of allergic and inflammatory mediators from mast cells that were isolated and purified 
from human skin tissue. Studies have shown that Resveratrol can inhibit mediator release 
from mouse mast cells (47, 50, 110). However, there are currently no studies showing the 
direct effect of Resveratrol on human mature mast cells, and the mechanism or target of 
Resveratrol has not been identified. Here, we identified the COX-2 pathway leading to 
PGD2 biosynthesis as a target for inhibition by Resveratrol at low concentrations. In 
addition, we uncover the ability of Resveratrol to enhance the production of TNF from 
human skin mast cells, a previously unrecognized pro-inflammatory effect. 
The finding that Resveratrol preferentially inhibited PGD2 production was 
corroborated by the observation that FcεRI-induced COX-2 expression but not Syk 
phosphorylation was inhibited by Resveratrol. In fact, Resveratrol failed to inhibit Syk 
phosphorylation even at an extremely high concentration (100 μM) that completely 
blocked downstream Akt, p38 or p42/44 phosphorylation. These findings provide the first 
evidence of preferential or selective inhibition of mediator release from human mature 
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mast cells by Resveratrol at concentrations more likely to be achieved 
physiologically. In addition, these data demonstrate that FcεRI-proximal Syk is not a 
target of Resveratrol. Interestingly, Resveratrol is a non-hydroxylated analog of naturally 
occurring piceatannol (3, 3′, 4, 5′-trans-trihydroxystilbene), a widely used inhibitor of 
Syk (111). The finding that FcεRI-induced COX-2 expression was inhibited with a 
relatively low concentration of Resveratrol, while phosphorylation of receptor-proximal 
Syk or downstream signaling molecules Akt, p38 or p42/44 was not, indicates that 
Resveratrol selectively targeted the FcεRI-induced eicosanoid biosynthesis pathway to 
inhibit PGD2 production. These data suggest that Resveratrol as a therapeutic agent might 
protect against allergic effects mediated by PGD2 but not against pre-formed mediators 
like histamine, which are stored in cytoplasmic granules and released during 
degranulation. 
Our data showing that Resveratrol at a relatively low concentration (10 μM) 
enhanced rather than inhibited TNF production was surprising given its reported anti-
inflammatory properties. Resveratrol and other polyphenols have been shown to inhibit 
TNF and other cytokines from human mast cells. One study demonstrated that 
Resveratrol (10 or 50 μM) inhibited cytokine production from the human mast cell line 
HMC-1 following stimulation with phorbol ester (PMA) + ionomycin (51). However, one 
critical difference from our study is that HMC-1 cells do not express FcεRI (112), and, 
thus, cannot be stimulated by IgE/Ag. Therefore, the signaling pathway(s) induced in 
HMC-1 transformed cells by PMA + ionomycin are likely distinct from those initiated by 
FcεRI crosslinking in normal primary mast cells used in our study. The flavones, luteolin, 
quercetin, and baicalein (1–100 μM) have also been shown to inhibit TNF and other 
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cytokines from human cultured mast cells, mast cell lines, or mouse BMMCs (113–116). 
Recently, the novel flavone tetramethoxyluteolin (methlut; 1–100 μM), a structural 
analog of luteolin, was shown to potently inhibit TNF production from IgE/anti-IgE-
activated human cord blood-derived mast cells or the LAD2 mast cell line (44). Our 
finding is supported by a recent study demonstrating an increase in plasma TNF levels in 
healthy subjects given oral Resveratrol (5 g), and in vitro (10 or 30 μM) from LPS-
stimulated human peripheral blood mononuclear cells or monocytes pre-treated with 
Resveratrol (117). Despite the numerous studies performed in mice or with mouse mast 
cells, there are no reported pro-inflammatory effects of Resveratrol or other polyphenols 
on allergic responses. Our finding and that of Gualdoni et al.  are the first pro-
inflammatory effects of Resveratrol on human primary immune cells to be reported. 
Therefore, the possibility exists that Resveratrol has different effects on human and 
mouse mast cells that have yet to be fully elucidated with regard to IgE-dependent 
responses. It is not currently known if the potentiating effect is specific to MCTC type 
mast cells in skin or if TNF production from MCT mast cells in lung is also enhanced. 
Nevertheless, it appears that in addition to its well-documented anti-inflammatory 
properties, Resveratrol has pro-inflammatory effects in humans that could dampen its 
potentially healthful benefits for which it has garnered intense interest. 
On the other hand, since Resveratrol is known to inhibit inflammation, it is 
possible that the increased amount of TNF induced by Resveratrol specifically from 
human skin mast cells is negated by Resveratrol's overall anti-inflammatory properties. 
The observed increase in TNF reported here could also represent a localized response to 
Resveratrol in human skin particularly with regard to allergic inflammation. If so, this 
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raises the issue of whether the overall physiological effect of Resveratrol is dependent on 
the route of delivery. This is particularly intriguing given that different methodologies to 
enhance the efficiency of topical administration of Resveratrol are currently being 
developed to deliver the polyphenol (118–122). Clearly, issues regarding route of 
delivery, solubility, and bioavailability will ultimately determine the efficacy of using 
Resveratrol or other polyphenols with limited solubility as therapeutic agents. 
The mechanism by which Resveratrol enhances TNF production from human skin 
mast cells is not known. However, an effect on the NF-κB pathway is suspected since 
NF-κB is required for IgE-dependent TNF production from mast cells (123). Indeed, 
enhanced TNF production by Resveratrol from LPS-stimulated human monocytes was 
associated with increased phosphorylation of p105, a component of the alternative 
pathway for NF-κB activation (45) suggesting that increased TNF production by 
Resveratrol could be due to increased NF-κB transcriptional activity. However, 
Resveratrol or other polyphenols were shown to inhibit NF-κB activation in human 
cultured mast cells, LAD2 or HMC-1 mast cell lines, or various transformed cell lines 
including U937, Jurkat, HeLa (51, 124, 125). One critical question that needs to be 
addressed is: If NF-κB activation is involved in Resveratrol-induced enhancement of 
TNF production, how do we reconcile this with the observations that NF-κB is inhibited 
with Resveratrol? To answer this, additional studies are needed to determine the effect of 
Resveratrol on canonical and non-canonical NF-κB activation in human mature mast 
cells. Nevertheless, our finding that FcεRI-induced phosphorylation of p38 or p42/44, 
which are involved in cytokine production from FcεRI-activated mast cells, was not 
altered with Resveratrol at a concentration that enhanced TNF production suggests a 
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target further downstream in the FcεRI pathway possibly NF-κB or other transcription 
factor(s). 
Resveratrol isomerization is known to be induced by the activation energy of solar 
or ultraviolet radiation (i.e. light) (126). Trans-Resveratrol is believed to be the primary 
and most stable natural form of this stilbene, and this isomer is associated with the 
multitude of Resveratrol’s reported biomedical health benefits (127). Additionally, trans-
Resveratrol is believed to be non-toxic while less is known about the safety of the cis-
isomer (126). For this reason, the present study involved the treatment of human skin 
mast cells with trans-Resveratrol. However, we failed to examine the isomerization of 
Resveratrol at the concentrations used, and so cannot be fully confident that the effects 
reported in this study are solely a product of trans-Resveratrol. In the future, nuclear 
magnetic resonance (NMR) should be employed to determine the isomerization of 
Resveratrol at low concentrations.  
Our study corroborates previous reports showing that high concentrations of 
Resveratrol inhibited mast cell degranulation and cytokine production. Here we show that 
Resveratrol at 100 μM strongly inhibited degranulation, PGD2 and cytokine production. 
However, whether the inhibitory effect with high concentrations of Resveratrol is 
physiologically relevant is questionable. It is unknown if human skin can absorb 50–
100 μM Resveratrol, the concentration range required to significantly inhibit 
degranulation, via topical application, but such high concentrations are unlikely to be 
achieved in tissues at least via oral route (128). Moreover, our data demonstrates that 
Resveratrol did not induce a loss in viability of human skin mast cells even at high 
concentrations indicating that the inhibitory effect was not due to cell toxicity. 
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Overall, we demonstrate that Resveratrol at relatively low concentrations: (1) 
preferentially inhibits the COX-2 pathway leading to PGD2 production; and (2) enhances 
TNF production from FcεRI-activated human skin mast cells. Together, these findings 
suggest that Resveratrol as a potential treatment for allergic reactions would be mostly 
effective against arachidonic acid-derived lipid mediators rather than histamine, but could 
also exacerbate or promote mast cell-mediated allergic inflammation in the skin.
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CHAPTER 5 
MATERIALS AND METHODS- INTERLEUKIN-6 POTENTIATES 
FCΕRI-INDUCED PGD2 BIOSYNTHESIS AND INDUCES VEGF FROM 
HUMAN IN-SITU-MATURED SKIN MAST CELLS
4
 
Interleukin-6 (IL-6) is a classical pro-inflammatory cytokine ubiquitously 
associated with pathological inflammation. In humans, IL-6 levels are correlated with 
severity or pathogenesis of allergic diseases including asthma, urticaria, and 
mastocytosis. The true role of IL-6 in allergic disease remains poorly understood, with 
particular reference to how it modulates mast cell function. Mast cells are capable of 
producing robust amounts of IL-6 when activated, but it had not been previously shown if 
mature in-situ-derived human skin mast cells were responsive to IL-6 signaling. The 
methods described in this section were designed to identify the presence of the 
membrane-bound IL-6 receptor on the surface of human skin mast cells and assess the 
function consequences of its signaling on inflammatory mediator production. Studies 
were performed on in-situ-matured human skin mast cells isolated in accordance with the 
University of South Carolina Internal Review Board (IRB). 
5.1 ISOLATION, PURIFICATION, AND CULTURE OF HUMAN SKIN MAST 
CELLS 
As described in Section 2.1. 
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5.2 IGE SENSITIZATION AND FCΕRI CROSSLINKING 
Mast cells (10
6
 cells/ml) were incubated in X-VIVO 15™ media containing SCF 
(100 ng/ml) and 1 μg/ml chimeric human anti-NP IgE (human Fc + mouse Fab) (clone 
JW8/1)(AbD Serotec, Raleigh, NC) overnight at 37
o
C, 5% CO2.  After washing to 
remove unbound IgE, the mast cells were re-suspended at 10
6
 cells/ml in X-VIVO 15™ 
media or Tyrode’s buffer (135 mM NaCl, 1 mM MgCl2, 20 mM Hepes, 5 mM KCl, 1.8 
mM CaCl2, 5.6 mM glucose; pH 7.4, 0.05% bovine serum albumin), and activated with 
the hapten 4-hydroxy-3-nitrophenylacetyl conjugated to bovine serum albumin at a 16:1 
molar ratio (NP-BSA; Biosearch Technologies, Novato, CA) at the indicated 
concentration at 37
o
C for the indicated amount of time. 
5.3 PGD2 AND DEGRANULATION ASSAYS 
Degranulation was measured by β-Hexosaminidase release assay.  After 
sensitization with anti-NP IgE, the mast cells were washed and resuspended at 10
6
 
cells/ml in Tyrode’s buffer, pre-treated as describe in figure legends, and activated with 
NP-BSA for 30 min.  After the activation period, mast cells and buffer were separated by 
centrifugation (2000 rpm × 5 min), and the pelleted cells were lysed with an equal 
volume of 1% Triton X-100.  β-Hexosaminidase activity in supernatant and cell lysate 
was determined by the release of p-nitrophenol from substrate p-nitrophenyl N-acetyl-β-
D-glucosaminide (pNAG; Sigma-Aldrich, St. Louis, MO) as described (98, 99).  In a 96-
well plate, 5 μl of supernatant or lysate were mixed with 45 μl of 4mM p-Nitrophenyl N-
acetyl-β-D-Glucosaminide (pNAG) in citric acid buffer (pH 4.5) and incubated for 1 h at 
37
o
C.  The reaction was stopped with 150 μl of 0.2 M glycine, pH 10.7.  Absorbance 
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values at 405 nm were acquired with a BioTek Synergy HT microplate reader (BioTek, 
Winooski, VT).  Percent β-hexosaminidase release was calculated from the absorbance 
values according to the formula: % β-hexosaminidase release = 
((supernatant)/(supernatant + lysate)) × 100.  PGD2 in the supernatants was measured by 
commercial assay (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s 
protocol. 
5.4 QUANTITATIVE REAL TIME PCR 
Gene expression was determined by quantitative real time PCR.  RNA was 
isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA).  cDNA was synthesized from 
total RNA with iScript cDNA Synthesis kit and PCR was performed using iQ SYBR
®
 
Green Supermix (Bio-Rad, Hercules, CA). The kits were used according to the 
manufacturer’s instructions. The PCR reaction mix was composed of 2 μl of cDNA, 1 μl 
each of sense and antisense primers (10 μM each) and 12.5 μl of iQ SYBR® Green 
Supermix in a final volume of 25 μl. A hot-start PCR protocol (95°C × 5 min, (95°C × 30 
sec, 55°C × 30 sec, 72°C × 30 sec) x 35 cycles, 95°C × 1 min, 55°C × 1 min) was 
performed on a CFX Connect Real Time PCR Detection System (Bio-Rad, Hercules, 
CA).  Fold change in expression was determined by the 2
ΔΔCt
 method with β2 
microglobulin (B2M) as the reference gene.  The oligonucleotide primers used were (5’-





Table 5.1: Primer sequences used for qRT-PCR. 
Gene Sequence 
VEGF F: CCATGCAGATTATGCGGATCAAA   
R: CACCAACGTACACGCTCCAG 
SOCS3 F: GCTCCAAGAGCGAGTACCAG  
R: CTGTCGCGGATCAGAAAGGT 
gp130 F: TCT GGGAGTGCTGTTCTGCTT 
R: TGTGCCTTGGAGGAGTGTGA 
IL-6Ra F: CTCATCTTTCTACAGACTACG   
R: GACCATCCATGTTGTGAATG 
COX-1 F: TCTTGCTGTTCCTGCTCCTG  
R: GTTGGAGCGCACTGTGAGTA 
COX-2 F: ACTGCTCAACACCGGAATTT   
R: CAAGGGAGTCGGGCAATCAT 
B2M F: TGGGTTTCATCCATCCGACA   
R: CTGCTTACATGTCTCGATCCC 
 
5.5 WESTERN BLOTTING 
10
6
 mast cells were lysed with 0.1 ml Tris-Glycine SDS Sample Buffer (Life 
Technologies, Carlsbad, CA) containing 1% β-mercaptoethanol and 1 mM Na3VO4.  
Protein equivalents of 5x10
5
 cells/lane were separated by SDS-PAGE, and then 
transferred onto nitrocellulose membranes.  After transfer, the membranes were blocked 
for 1 h at room temperature with Odyssey Blocking Buffer (LI-COR Biosciences, 
Lincoln, NE).  Two-color staining for total and phosphorylated STAT3 was performed 
with the primary antibodies Stat3 (79D7) rabbit mAb and phospho-STAT3 
(Tyr705)(3E2) mouse mAb or phospho-STAT3 (Ser727)(6E4) mouse mAb (Cell 
Signaling Technology, Danvers, MA), and secondary antibodies goat anti-rabbit IRDye 
680RD and goat anti-mouse 800CW (LI-COR Biosciences, Lincoln, NE).  The blots 
were incubated overnight at 4
o
C with primary antibodies, and for 1 h at room temperature 
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with secondary antibodies.  The blots were scanned on an Odyssey
®
 CLx Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE). 
5.6 FLOW CYTOMETRY 
Human skin mast cells (10
6
) were washed with FACS buffer (1% BSA, 0.04% 
NaN3 in PBS), and Fc receptors were blocked with Human TruStain FcX™ (5 µl/10
6
 
cells) (BioLegend, San Diego, CA) and 1% normal human serum for 15 min on ice to 
prevent non-specific binding.  The mast cells were then stained with PE-labeled anti-
human CD130 (gp130) (clone 2E1B02), CD126 (IL-6Rα) (clone UV4), FcεRIα (clone 
AER-37 (CRA-1)), or respective isotype control, mouse IgG2a,k, IgG1,k, IgG2b,k 
(BioLegend, San Diego, CA) for 1 h on ice.  After washing twice, the mast cells were re-
suspended in 200 µl FACS buffer and run on a Beckman Coulter Cytomics FC500.  Data 
was analyzed with FlowJo software (FlowJo LLC, Ashland, OR). 
5.7 CYTOKINE MEASUREMENTS 
Mast cells (10
6
 cells/ml) were sensitized with anti-NP IgE, pre-treated or not with 
IL-6 as indicated, and activated with NP-BSA for 24 h at 37
o
C in X-VIVO 15™ media 
containing SCF (100 ng/ml) and soybean trypsin inhibitor (100 μg/ml) (SBTI; Sigma-
Aldrich, St. Louis, MO).  After the activation period, mast cells and media were 
separated by centrifugation (2000 rpm x 5 min), and secreted cytokines in supernatant 
were measured by enzyme-linked immunosorbent assay (ELISA).  VEGF was measured 
using commercial kits (R&D Systems, Minneapolis, MN) according to the 
manufacturer’s protocol.  TNF and IL-8 were measured using capture (purified) and 
detection (biotinylated) rat antibodies, and serially diluted recombinant cytokine 
46 
standards for standard curves (BD Biosciences, San Jose, CA) in a 384-well format as 
described (100).  The plates were developed with the substrate peroxidase 2,2’-azino-bis-
3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma-Aldrich, St. Louis, MO).  
Absorbance values at 405 nm were obtained with a BioTek Synergy HT microplate 
reader (BioTek, Winooski, VT), and cytokine concentrations determined using Gen5 
Data Analysis Software. 
5.8 STATISTICAL ANALYSIS 
As described in Section 2.8.
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CHAPTER 6 
RESULTS- INTERLEUKIN-6 POTENTIATES FCΕRI-INDUCED PGD2 
BIOSYNTHESIS AND INDUCES VEGF FROM HUMAN IN-SITU-
MATURED SKIN MAST CELLS
 5
 
6.1 HUMAN SKIN MAST CELLS CONSTITUTIVELY EXPRESS MEMBRANE-
BOUND GP130 AND IL-6RΑ 
The IL-6 receptor is comprised of gp130 and IL-6Rα subunits.  Gp130 is a 
membrane bound protein whereas IL-6Rα exists as membrane-bound and secreted forms.  
Both gp130 and IL-6Rα have been shown expressed on in vitro-derived mast cells (70, 
73), but their expression on human in situ-matured mast cells had not been reported.  
Here, we demonstrate by flow cytometry that human skin mast cells constitutively 
express gp130 (Figure 6.1A) and membrane-bound IL-6Rα (Figure 6.1C) on their 
surface. Net Mean Fluorescence Intensity (MFI) of gp130 staining was 778 ± 89 
compared to 204 ± 9 for IgG isotype control (n=3, p=0.003) (Figure 6.1B), and of IL-6Rα 
staining was 937±37 compared to 722.5 ± 7.5 for IgG isotype control (n=3, p=0.03) 
(Figure 6.1D).  Because mouse bone marrow-derived mast cells (BMMCs) reportedly 
require IL-10 for gp130 expression (129), we determined the effect of IL-10 on gp130 
expression on human skin mast cells.  Interestingly, treatment with IL-10 (10 ng/ml) for 
24 h resulted in a significant increase in gp130 mRNA expression (3.5 ± 0.7 fold change, 
n=3, p=0.02) (Figure 6.1E), but did not enhance the surface expression of gp130 (Figure 
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6.1F).  Thus, primary in situ-matured mast cells from human skin constitutively 
express gp130 and membrane bound IL-6Rα. 
6.2 HUMAN SKIN MAST CELLS EXPRESS FUNCTIONAL MEMBRANE 
BOUND RECEPTORS FOR IL-6 CAPABLE OF TRANSMITTING POTENT IL-
6-INDUCED SIGNALS VIA CLASSICAL SIGNALING 
The constitutive expression of gp130 and membrane bound IL-6Rα on human 
skin mast cells suggested that these cells could be directly stimulated by IL-6 via classical 
signaling.  To determine if gp130 and IL-6Rα subunits formed functional signaling 
complexes, we analyzed the phosphorylation status of Signal Transducer and Activator of 
Transcription 3 (STAT3), a known target of gp130 signals that is implicated in mast cell 
degranulation and anaphylaxis reactions (130–132), in human skin mast cells stimulated 
with IL-6.  As demonstrated with Western blot, stimulation of human skin mast cells for 
15 minutes with 1, 10 or 100 ng/ml of recombinant IL-6 induced a dose-dependent 
increase in STAT3 phosphorylation (Figure 6.2A, left side).  For comparison, we 
stimulated skin mast cells in parallel with IL-27, which also utilizes gp130 and has been 
implicated in the regulation of mast cells and human allergic disease (133–136).  As 
expected, IL-27 induced STAT3 phosphorylation (Figure 6.2A, right side).  However, 
STAT3 phosphorylation induced with IL-6 was significantly and dramatically greater 
than that induced by IL-27 (Figure 6.2B); thus, demonstrating the potency of IL-6 
induced gp130 signals.  Next, we analyzed the expression of Suppressor of Cytokine 
Signaling 3 (SOCS3), a downstream target of STAT3, in human skin mast cells 
stimulated with IL-6 or IL-27.  In time-course experiments, SOCS3 mRNA expression 
was rapidly induced, peaking within 1h of treatment with 100 ng/ml of IL-6 (Figure 
6.2C) or IL-27 (Figure 6.2D).  Reflective of the difference in intensity of STAT3 
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phosphorylation induced by IL-6 or IL-27, the IL-6-induced increase in SOCS3 mRNA 
was dramatically greater than that induced with IL-27 at 1 h post-treatment (362 ± 128 
versus 9 ± 0.3).  By 3 h post-treatment, the SOCS3 mRNA level in IL-27-treated mast 
cells had returned to baseline levels, and in IL-6-treated mast cells was considerably 
reduced with continued temporal regression.  Thus, human skin mast cells express 
functional membrane-bound IL-6 receptors capable of transmitting highly potent gp130 
signals via direct stimulation with IL-6 (classical signaling).  
6.3 IL-6 HAS NO EFFECT ON FCΕRI-INDUCED DEGRANULATION OF 
HUMAN SKIN MAST CELLS 
IL-6 was recently shown to enhance the degranulation of in vitro-derived CBMCs 
(73).  Therefore, given the association between severity of allergic disease and IL-6 in 
humans, we sought to determine the effect of IL-6 on FcεRI-induced degranulation of 
human in situ-matured mast cells.  Human skin mast cells were sensitized with chimeric 
human anti-NP IgE, pre-treated with 1, 10 or 100 ng/ml of recombinant human IL-6 for 1 
h, and then challenged with NP-BSA (100 ng/ml) for 30 min.  Degranulation was 
determined by β-hexosaminidase assay.  As demonstrated, IL-6 had no effect on FcεRI-
induced degranulation of human skin mast cells (Figure 6.3A).  In the converse set of 
experiments, IgE-sensitized human skin mast cells were pre-treated or not with IL-6 at a 
high concentration (100 ng/ml), and then challenged with 0.1, 1, 10, or 100 ng/ml of NP-
BSA.  As shown, IL-6 at failed to enhance degranulation induced with a dose range of 
NP-BSA representing sub-maximal to maximal levels of FcεRI crosslinking (Figure 
6.3B).  Noteworthy, IL-6 failed to enhance degranulation of human skin mast cells even 
at a concentration (100 ng/ml) that strongly induced the phosphorylation STAT3 (Figure 
6.2A), which has itself been implicated in mast cell degranulation (130–132). Since 
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human MCTC mast cells are known to spontaneously secrete IL-6 (Figure 6. 3C) (71), and 
prolonged exposure to IL-6 was reported to enhance degranulation of in vitro-derived 
cord blood-derived mast cells (CBMCs) (73), we sought to determine if the potential or 
capacity of skin mast cells for degranulation was somehow affected by endogenous IL-6.  
To address this, we cultured human skin mast cells with neutralizing anti-IL-6 antibody 
(1 μg/ml) or isotype control for up to 3 days, and measured FcεRI-induced degranulation 
at daily intervals.  As shown, β-hexosaminidase release from mast cells cultured with 
neutralizing anti-IL-6 antibody was nearly identical to that from mast cells cultured with 
non-specific IgG control or media alone at each time-point (Figure 6.3D).  Thus, gp130 
signaling initiated by exogenous IL-6 does not enhance or inhibit FcεRI-induced 
degranulation of human skin mast cells.  Moreover, long term exposure to endogenously 
produced IL-6 does not appear to influence the capacity or potential of human skin mast 
cells for degranulation.  
6.4 IL-6 POTENTIATES FCΕRI-INDUCED PGD2 BIOSYNTHESIS 
Mast cells are major producers of PGD2 (34), a critical component of allergic 
airways inflammation (39).  Since IL-6 had no effect on mast cell degranulation, we 
sought to determine the effect on FcεRI-induced PGD2 biosynthesis.  To do so, IgE-
sensitized human skin mast cells were pre-treated with 1, 10, or 100 ng/ml of IL-6 for 1 
h, and then challenged with NP-BSA (100 ng/ml) for 30 min.  PGD2 in cell-free media 
was quantified by enzyme immunoassay.  As shown, IL-6 significantly and dose-
dependently enhanced the amount of PGD2 secreted from FcεRI-activated human skin 
mast cells (Figure 6.4A).  In the converse set of experiments, IgE-sensitized human skin 
mast cells were pre-treated or not with IL-6 (100 ng/ml) and then challenged with 0.1, 1, 
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10, or 100 ng/ml of NP-BSA.  As shown, mast cells treated with IL-6 produced more 
PGD2 than control mast cells with significant differences detected with NP-BSA at 10 
ng/ml or 100 ng/ml (Figure 6.4B).  Thus, IL-6 potentiates FcεRI-induced PGD2 
biosynthesis from human skin mast cells. 
6.5 IL-6 ENHANCES FCΕRI-INDUCED COX-2 EXPRESSION AND PGD2 
PRODUCTION BY A STAT3-DEPENDENT MECHANISM 
To begin to understand the mechanism, we analyzed the effect of IL-6 on 
expression of COX-1 and COX-2, key enzymes in the eicosanoid pathway leading to 
prostaglandin biosynthesis (102). Human skin mast cells were sensitized with anti-NP 
IgE, pretreated with 100 ng/ml or a dose range of 1 – 100 ng/ml of IL-6 for 1 h, and then 
activated with NP-BSA (100 ng/ml) for 1 h.  Changes in expression of COX-1 and COX-
2 were determined by quantitative real time PCR.  As expected since COX-2 is an 
inducible enzyme whereas COX-1 is constitutively expressed, the expression of COX-2, 
but not COX-1, was induced with FcεRI crosslinking (Figure 6.5A and C).  In accordance 
with the ability to potentiate PGD2 biosynthesis (Figure 6. 4), IL-6 significantly enhanced 
the FcεRI-induced expression of COX-2 (Figure 6.5A and B).  IL-6 alone had no effect 
on the expression of either enzyme.  Noteworthy, IL-6 had no effect on expression of 
hematopoietic prostaglandin D synthase (HPGDS), which catalyzes the conversion of 
prostaglandin H2 (PGH2) to PGD2 [45], or RasGRP4, which regulates HPGD2S 
expression in mast cells (137) (not shown). 
To confirm that the IL-6-induced increase in COX-2 and PGD2 was due to 
STAT3 activation, we used the small molecule inhibitor of STAT-3 tyrosine 
phosphorylation C188-9 (138).  First, we determined the efficacy of C188-9 to inhibit IL-
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6-induced STAT3 phosphorylation at the activating tyrosine 705 in human skin mast 
cells.  In dose curve experiments, human skin mast cells were pre-treated or not with 
C188-9 (6.25 to 100 μM) for 1 h, and then stimulated with IL-6 (100 ng/ml) for 15 min.  
STAT3 phosphorylation was determined by Western blot analysis of whole cell lysates.  
As shown, C188-9 dose-dependently inhibited the IL-6-induced phosphorylation of 
STAT3 at the Y705 (Figure 6.5D). Next, we sought to determine if C188-9 would inhibit 
the IL-6-induced enhancement of FcεRI-induced COX-2 expression.  Human skin mast 
cells were sensitized with anti-NP IgE, pre-treated with C188-9 (25 μM) for 1 h, and then 
stimulated with IL-6 (100 ng/ml) for 1 h.  The mast cells were then activated with NP-
BSA (10 ng/ml) for an additional 1 h.  As demonstrated by quantitative real-time PCR, 
C188-9 completely inhibited the IL-6-induced increase in COX-2 expression (Figure 
6.5E).  Similarly, C188-9 was shown to be highly effective at inhibiting the IL-6-induced 
biosynthesis of PGD2 (Figure 6.5F). Together, these data confirm that the enhancing 
effect of IL-6 on FcεRI-induced PGD2 biosynthesis and COX-2 expression was indeed 
due to STAT3 activation.   
6.6 IL-6 INDUCES VEGF PRODUCTION AND ENHANCES FCΕRI-INDUCED 
IL-8 SECRETION. 
The ability of mast cells to produce VEGF is abundantly documented (139).  
Having shown that human skin mast cells express functional membrane-bound IL-6Rα 
and gp130, we sought to determine if classical signaling with IL-6 could induce or 
enhance FcεRI-induced VEGF production from these cells.  To do so, human skin mast 
cells were sensitized with anti-NP IgE, pre-treated with 1, 10, or 100 ng/ml of IL-6 for 1 
h, and then challenged with NP-BSA (100 ng/ml) for 24 h.  Secreted VEGF, IL-8 and 
TNF in supernatants were measured with ELISA.  As shown, IL-6 alone induced a 
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significant increase in secretion of VEGF compared to untreated skin mast cells (Figure 
6.6A).  A similar increase in VEGF secretion was also observed from FcεRI-activated 
mast cells pre-treated with IL-6 indicating an additive rather than potentiating effect. To 
confirm that VEGF production was induced directly with IL-6, we treated non-sensitized 
human skin mast cells with IL-6 (100 ng/ml), and measured changes in VEGF mRNA 
expression at 1, 3, 6, 12, and 24 h by quantitative real-time PCR.  As shown, VEGF 
mRNA expression was increased >3-fold at 6 hours post IL-6, and remained elevated at 
12 and 24 h compared to untreated mast cells (Figure 6.6B).  We further demonstrate that 
the IL-6-induced production of VEGF was inhibited with C188-9, the inhibitor of STAT3 
phosphorylation at the activating tyrosine 705 (Figure 6.6C).  Thus IL-6 alone can induce 
VEGF production by a STAT3-dependent mechanism in human in situ-matured mast 
cells.  IL-6 alone did not induce IL-8 production, but significantly enhanced FcεRI-
induced IL-8 secretion (Figure 6.6D).  In contrast, IL-6 had no effect on production of 
TNF (Figure 6.6E).   
6.7 FCΕRI AND GP130 SIGNALS SYNERGIZE TO ENHANCE STAT3 
PHOSPHORYLATION 
STAT3 phosphorylation occurs at two main residues: tyrosine 705 and serine 727.  
Initial phosphorylation at Y705 activates STAT3 (140, 141), whereas phosphorylation at 
S727 is required for maximal transcriptional activity of STAT3 (142).  To determine the 
effect of FcεRI signaling on IL-6-induced STAT3 phosphorylation, human skin mast 
cells were sensitized with anti-NP IgE, and treated with IL-6 (100 ng/ml), NP-BSA (100 
ng/ml), or IL-6 + NP-BSA for 15 min.  STAT3 phosphorylation at Y705 and S727 was 
determined by Western blot analysis of whole cell lysates (Figure 6.7).  As expected, IL-
6 alone strongly phosphorylated STAT3 at Y705, but, surprisingly, did not phosphorylate 
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S727.  Conversely, FcεRI signals alone did not phosphorylate STAT3 at Y705, but, 
interestingly, did phosphorylate S727 albeit at low but detectable levels.  Importantly, 
phosphorylation of STAT3 at both Y705 and S727 was increased in human skin mast 
cells treated with IL-6 + NP-BSA.  Thus, signals from FcεRI and gp130 synergize to 




Figure 6.1: Human skin mast cells constitutively express membrane-bound IL-6Rα 
and gp130. Human skin mast cells at rest were stained with PE-labeled anti-gp130 or 
anti-IL-6Rα and analyzed by flow cytometry (A, C). Significance was determined by 
analysis of Mean Fluorescence Intensity (MFI) (B, C). The effect of IL-10 on gp130 
expression was determined by culturing human skin mast cells with IL-10 (10 ng/ml) for 
24 h, and analyzing gp130 gene expression by quantitative real-time PCR (E) and surface 
expression by flow cytometry (F). Bars represent mean ± S.E.M. of values from 3 
separate experiments with mast cells from different donors. Significance was determined 














Figure 6.2: IL-6 induces STAT3 phosphorylation and SOCS3 expression via classical 
signaling in human skin mast cells. To determine the functionality of membrane-
bound gp130 and IL-6Rα, STAT3 phosphorylation and SOCS3 expression was analyzed 
in IL-6-treated human skin mast cells. For comparison, parallel studies were performed 
with IL-27, which also utilizes gp130. STAT3 phosphorylation was determined by SDS-
PAGE and Western blotting of whole cell lysates prepared from skin mast cells treated 
with IL-6 or IL-27 at 1, 10, or 100 ng/ml for 15 min (A). STAT3 phosphorylation was 
quantified with Western blot band intensities (B). SOCS3 expression was determined by 
quantitative real-time PCR of total RNA from skin mast cells treated with IL-6 
(100 ng/ml) (C) or IL-27 (D) for 1, 3, 6, 12, or 24 h. Fold change was calculated using the 
2
ΔΔCt
 method with B2M as the reference gene. >2-fold change was considered significant. 
Bars represent mean ± S.E.M. of values from 3 separate experiments with mast cells from 
different donors. Significance was determined with Student's t-test. **, p < 0.01 and 
***, p < 0.001. Representative blot is shown. 
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Figure 6.3:  IL-6 does not induce or enhance FcεRI-induced degranulation of human 
skin mast cells. Human skin mast cells were sensitized with anti-NP IgE, and challenged 
with NP-BSA for 30 min. Degranulation was determined with β-hexosamindase release 
assay. (A) Dose-dependent effect of IL-6 on FcεRI-induced degranulation induced with 
NP-BSA (100 ng/ml). (B) Effect of IL-6 (100 ng/ml) on degranulation induced with NP-
BSA at 0.1, 1, 10, or 100 ng/ml. (C) Spontaneous release of IL-6. The amount of IL-6 
and TNF in 7-day culture media of mast cells was quantified with ELISA. Each data 
point represents mast cells from a single donor (n = 5). (D) Effect of endogenously 
produced IL-6 on degranulation. Mast cells were cultured with neutralizing anti-IL-
6 mAb or isotype control (1 μg/ml) for 24, 48, or 72 h, and degranulation was determined. 
Bars represent mean ± S.E.M. of values from at least 3 different experiments with mast 




Figure 6.4: IL-6 potentiates FcεRI-induced PGD2 biosynthesis from human skin mast 
cells. To determine the effect of IL-6 on PGD2 production, human skin mast cells were 
sensitized with anti-NP IgE, pre-treated with IL-6 for 1 h, and then challenged with NP-
BSA for 30 min. IgE-sensitized human skin mast cells were pre-treated with IL-6 at 1, 10, 
or 100 ng/ml, and then challenged with NP-BSA (A), or pre-treated with IL-6 
(100 ng/ml) and challenged with NP-BSA at 1, 10, or 100 ng/ml (B). Secreted PGD2 in 
cell-free supernatants was measured by enzyme immunoassay. Bars represent 
mean ± S.E.M. of values from at least 3 separate experiments with mast cells from 












Figure 6.5: IL-6 enhances FcεRI-induced COX-2 expression and PGD2 biosynthesis by a 
STAT3-dependent mechanism in human skin mast cells. IgE-sensitized mast cells were 
pre-treated with IL-6 (100 ng/ml) for 1 h, and challenged with NP-BSA (100 ng/ml) for 
1 h. The effect of IL-6 on FcεRI-induced expression of COX-2 (A, B) and COX-1 (C) 
was determined by quantitative real-time PCR. (D) Western blotdemonstrating the 
efficacy of C188-9 to inhibit IL-6-induced STAT3 phosphorylation. (E) Quantitative 
real-time PCR analysis showing that C188-9 inhibits IL-6-enhanced COX-2 expression. 
(F) Inhibition of IL-6-induced potentiation of FcεRI-induced PGD2biosynthesis with 
C188-9 (25 μM). Graph bars represent mean ± S.E.M. of values from 3 separate 
experiments with mast cells from different donors. Significance was determined with 















Figure 6.6: IL-6 induces VEGF synthesis and enhances FcεRI-induced IL-8 production in 
human skin mast cells. Human skin mast cells were sensitized with anti-NP IgE, pre-
treated with IL-6 at 1, 10, or 100 ng/ml for 1 h, and then challenged with NP-BSA 
(100 ng/ml) for 24 h. Secreted VEGF (A, C), IL-8 (D) and TNF (E) in cell-free media 
were measured with ELISA. (B) IL-6-induced VEGF mRNA expression was analyzed by 
quantitative real-time PCR using total RNA isolated from mast cells treated with IL-6 
(100 ng/ml) for 1, 3, 6, 12, and 24 h. >2-fold change was considered significant. (C) 
C188-9 inhibits IL-6-induced VEGF production. Bars represent mean ± S.E.M. of values 
from 3 separate experiments with mast cells from different donors. Significance was 














Figure 6.7: FcεRI and gp130 signals synergize to enhance STAT3 phosphorylation in 
human skin mast cells. Western blot showing phosphorylation of STAT3 at tyrosine 705 
and serine 727. Human skin mast cells were sensitized with anti-NP IgE, and then treated 
with IL-6 (100 ng/ml), NP-BSA (100 ng/ml), or IL-6 + NP for 15 min. STAT3 
phosphorylation was determined by SDS-PAGE and Western blot analysis of whole cell 









DISCUSSION- INTERLEUKIN-6 POTENTIATES FCΕRI-INDUCED 
PGD2 BIOSYNTHESIS AND INDUCES VEGF FROM HUMAN IN-SITU-
MATURED SKIN MAST CELLS
6
 
This study was designed to determine the ability of IL-6 to signal into in-situ 
matured human skin mast cells, and characterize any functional effects of this signaling. 
These experiments revealed the mechanism by which IL-6 exerts its effects on mast cells, 
and how this signaling modifies mediator release. 
Surface staining by flow cytometric analysis revealed that in-situ matured humans 
skin mast cells constitutively express both components required for the functional IL-6 
receptor; signal-transducing gp130 and ligand-binding IL-6Rα. This was not altogether 
surprising, as it is believed that gp130 is ubiquitously expressed on most cell types while 
expression of the alpha portion (IL-6Rα)  is restricted to immune cells and hepatocytes 
(54, 143). gp130 surface expression had been reported on  BMMCs, but it was shown to 
require administration of exogenous IL-10 (129). However, after examining the effects of 
IL-10 on our human skin mast cells, it was revealed that while IL-10 does increase gp130 
transcript, the surface expression remains unchanged. Interestingly, both IL-6Ra and 
gp130 are found in the blood in soluble form (144). sIL-6Ra is produced upon proteolytic 
cleavage by ADAM10/17, while sgp130 production is generally accomplished through 
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 Parts of this chapter have been excerpted from the following research article: 
McHale, C., Z. Mohammed, J. Deppen, and G. Gomez. 2018. Interleukin-6 potentiates FcεRI-
induced PGD2 biosynthesis and induces VEGF from human in situ-matured skin mast cells. 
Biochim. Biophys. Acta - Gen. Subj. 1862. 
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alternative splicing (145).  Constitutive expression of the complete IL-6R on 
huSMCs is consistent with the belief that most circulating sIL-6Ra originates from 
myeloid cells, a lineage in which mast cells are included (143). In fact, most of the 
harmful pathological effects of IL-6 are believed to be due to IL-6 trans-signaling rather 
than classical signaling, which aligns with the expression patterns of membrane-bound 
IL-6Ra and gp130. However, this does beg the question of how much, if any, sIL-6Ra 
mast cells are capable of releasing into their environment. We do not address this topic 
here, but it represents an interesting avenue to pursue in addition to exploring the 
proteolytic activity of ADAM10/17 in huSMCs. However, it was shown recently that 
human cord blood-derived mast cells (CBMC) spontaneously produce both sIL-6Rα and 
sgp130 at similar levels. Notably, sIL-6Rα production was dose-dependently decreased 
by IL-6 and showed significant reduction at 100 ng/ml. Inhibition of ADAMs 10 and 17 
also resulted in a suppression of sIL-6Rα by LAD2 mast cells (73).  
Upon discovering the constitutive expression of the complete IL-6 receptor, the 
next step was to validate the ability of IL-6 to transmit a signal inside the cell. IL-6 
signaling has been well-studied in other cell types, and at this point the pathway can be 
considered canonical. Briefly, binding of IL-6 to IL-6Rα results in receptor dimerization 
which activates both the JAK/STAT3 and SHP2/Gab/MAPK pathways. Here, we focus 
solely on the characterization of the JAK/STAT3 pathway. The gp130-associated Janus 
Kinases (Jaks). Activated Jaks then serve as docking sites for the SH2 domain-containing 
Signal Transducer and Activator of Transcription 3 (STAT3), which are then 
subsequently phosphorylated. Activated STAT3 then dimerizes and translocates to the 
nucleus to exert its effects on gene expression. One of the genes upregulated by STAT3 is 
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the Suppressor of Cytokine Signaling 3 (SOCS3), which acts as a negative regulator of 
IL-6 signaling by inhibiting Jak. Since STAT3 phosphorylation is a hallmark of gp130 
signaling, we used its activation status to assess the ability of IL-6R to signal into 
huSMCs. For comparative analysis, we also assessed the ability of IL27, another gp130-
utilizing cytokine, to phosphorylate STAT3. Both IL-6 and IL-27 dose-dependently 
increased the phosphorylation of STAT3 at Y705 after 15 minutes of activation. 
Interestingly, when applied at the same concentrations, IL-6 induced STAT3 
phosphorylation at twice the magnitude of IL-27. This is likely due to differences in 
expression of the ligand-binding portion of each receptor.  In data not shown here, the 
expression of the ligand-binding portion of the IL-27 receptor, WSX-1, was undetectable 
by flow cytometry surface staining (136). Assessment of SOCS3 mRNA induction by IL-
26 or IL-27 revealed similar results. IL-6 treatment caused a 362 ± 128-fold increase in 
SOCS3 message while IL-27 treatment resulted in a 9 ± 0.3-fold increase. While both 
cytokines increased SOCS3 expression, the level of upregulation corresponds to the 
intensity of STAT3 phosphorylation. Together, this data shows that IL-6 initiates a much 
stronger gp130 signal compared to other gp130-utilitzing cytokines. This is an interesting 
phenomenon to consider since the purpose of SOCS3 is to attenuate JAK/STAT-utilizing 
cytokine signaling. Thus, it appears that a strong gp130 signal induced by IL-6 requires 
an equally strong response by SOCS3 to inhibit and regulate the inflammatory effects of 
IL-6 signaling.  
Knowing that the functional IL-6 receptor was constitutively expressed on the 
surface of human skin mast cells, the next logical step was to address the effects of IL-6 
on the release of inflammatory mediators. As outlined previously, mast cells generally 
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release mediators in one of three ways: degranulation of pre-formed compounds, de-novo 
synthesis of proteins, and biosynthesis of membrane-derived eicosanoids. These three 
pathways generally occur temporally in that respective order. In contrast to a recent study 
demonstrating that IL-6 could enhance degranulation of in-vitro-derived mast cells, we 
show no evidence to support an enhancing effect in huSMCs (Desai/Metcalfe) We 
arrived at this conclusion after testing the effect of IL-6 pre-treatment on huSMC 
degranulation in two ways: (1) we pre-treated IgE-sensitized cells with IL-6 at 1, 10, or 
100 ng/ml for 1 hr and  then challenged them with NP-BSA (100 ng/ml) for 30 mins and 
(2) we pre-treated IgE-sensitized cells with IL-6 (100 ng/ml) for 1 hr and then challenged 
them with NP-BSA at 0.1, 1, 10, or 100 ng/ml for 30 mins. In both cases, cells showed no 
significant changes in FcεRI-XL-dependent or independent degranulation as quantified 
by beta-hexosaminidase assay. Of note, it was established by Oskeritzian et al. that mast 
cells spontaneously produce and release IL-6 (71). Knowing this, we sought to determine 
if endogenously-produced IL-6 was sensitizing the cells to the cytokine’s effects, perhaps 
inhibiting exogenously added IL-6 from inducing degranulation. Cells were cultured for 
24, 48, and 72 hours with media alone, isotype control, or IL-6 neutralizing antibody. 
After challenge with NP-BSA and subsequent assay for degranulation, we determined 
that endogenously produced IL-6 also did not affect huSMC degranulation. The lack of 
an effect on degranulation is a surprising response, as STAT3 has been implicated in 
mast cell degranulation by several studies (130–132). Specifically, it was reported that 
STAT3 is critical for human mast cell degranulation while being disposable for murine 
mast cell degranulation (132). Moreover, STAT3 itself has been closely linked to allergic 
disease (131). This is unlikely, as STAT3 would be equally involved in mediating mast 
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cell degranulation across species if it were indispensable. It is unclear why IL-6 has 
inconsistent effects on degranulation in in-vitro-derived and in-situ matured human mast 
cells, although several factors could contribute. Namely, the phenotype acquired by the 
cells during maturation and development is certainly different between in-vivo and in-
vitro grown mast cells. It is also possible that IL-6 has pleiotropic effects on mast cells of 
different phenotypes or from different tissues, as it was shown to protect lung MCT cells 
from apoptosis but had no effect on lung or skin MCTC mast cells (71). Additionally, IL-6 
is typically added to CBMC cultures to induce in-vitro development which may prime the 
mast cells to respond differently to exogenously administered IL-6 (146). In-situ-matured 
human skin mast cells only required added SCF, not IL-6, when cultured in-vitro. 
Together, the data generated here and that present in the current literature shows that 
further experimentation is required to determine the role of IL-6 and STAT3 in mast cell 
degranulation.  
We next sought to determine the effect of IL-6 signaling on mast cell eicosanoid 
production by specifically looking at biosynthesis of PGD2. PGD2 has been shown to be a 
major contributor to the development of allergic asthma and is a known product of human 
skin mast cell FcεRI crosslinking. In fact, robust quantities of PGD2 are produced in mere 
minutes following FcεRI XL, where it is released into the environment to induce 
bronchoconstriction and vasodilation. Pre-treatment with IL-6 at 1, 10, or 100 ng/ml and 
subsequent FcεRI XL revealed the ability of IL-6 to dose-dependently potentiate the 
production of PGD2 in human skin mast cells. Additionally, pre-treatment with IL-6 (100 
ng/ml) and succeeding dose-dependent challenge with NP-BSA yielded similar results. 
Notably, PGD2 production peaked when IL-6 pre-treated cells were challenged with NP-
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BSA at 10 ng/ml rather than the maximal 100 ng/ml. This suggests that maximal FcεRI 
aggregation may actually be suboptimal for greatest PGD2 production. This is similar to 
an effect seen in BMMCs in our own lab, where DNP-HSA challenge at maximal 
amounts produces an inhibitory effect on degranulation.  
As outlined previously, PGD2 is produced by the liberation of arachidonic acid 
from the plasma membrane by cPLA2. Subsequently, it undergoes enzymatic 
modification by cyclooxygenases into a common prostaglandin intermediate. Many 
investigators have shown that COX-2 is the only inducible enzyme in this pathway, and it 
is well-established that COX-1 is constitutively expressed regardless of cellular 
stimulation (147). Knowing this, we hypothesized that IL-6 was causing this potentiating 
effect on PGD2 production by modulating COX-2 expression. Indeed, after performing 
RT-PCR on IL-6-treated cells, it was revealed that COX-2 was highest in those cells pre-
treated with IL-6 and then challenged with NP-BSA compared to IL-6 or NP-BSA alone. 
The increase in transcript levels in IL-6 pre-treated cells compared with FcεRI XL alone 
was significant, about two-fold. Concurrently, COX-1 message levels remained 
consistent regardless of treatment as expected. Induction of COX-2 by IL-6 is consistent 
with previous work done with macrophages, showing that IL-6 induced COX-2 and PGE 
Synthase-1 (148). The ability of IL-6 to potentiate FcεRI-XL-dependent PGD2 production 
is a novel finding and potentially represents a new mechanism in allergic disease. IL-6 
levels are repeatedly correlated with severity of allergic disease, and mast cells and PGD2 
are known to contribute to asthma pathogenesis. Together, these findings suggest a 
mechanism in which IL-6 contributes to asthma development and severity by increasing 
PGD2 production in mast cells by classical signaling.  
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The concurrent increases in COX-2 expression and PGD2 production by IL-6 
suggest a STAT-3 dependent mechanism is responsible for these effects. However, 
activation of the IL-6 receptor is known to cause signal transmission through other 
pathways, including PI3K and MAPK (59). To determine if signaling through STAT3 is 
solely responsible for increasing COX-2 and PGD2, we used an inhibitor of STAT Y705 
phosphorylation, C188-9, to abolish IL-6 signaling. Pre-treatment of mast cells with 
C188-9 and subsequent activation with IL-6 revealed C188-9’s ability to dose-
dependently inhibit gp130-induced STAT3 phosphorylation. Further experiments showed 
that C188-9 abolished IL-6 induced COX-2 expression and PGD2 production (Fig. 4.5E 
and F). The ability of C188-9 to selectively inhibit FcεRI-dependent IL-6-induced COX-
2 expression and PGD2 production proves this a STAT-3-dependent mechanism.    
Chronologically, the final stage of FcεRI XL-dependent mediator release is the 
production of de-novo cytokines, chemokines, and growth factors. Collectively, this 
group of proteins is responsible for the late phase effects of allergic reactions like cellular 
recruitment and subsequent infiltration. Literature on the IL-6 signaling pathway 
provided clues to several proteins that may be IL-6-responsive. To isolate released 
proteins, we pre-treated cells with IL-6 at varying concentrations and then activated them 
with NP-BSA for 24 hrs. After activation, the cell-free supernatants were then subjected 
to various ELISAs. Using this method, we identified the ability of IL-6 alone to increase 
spontaneous production of VEGF and MCP-1, and to potentiate the FcεRI-XL-dependent 
production of VEGF and IL-8. Of note, FcεRI XL appears to significantly decrease 
production of MCP-1 in contrast to its effects on VEGF, IL-8, and TNFα (Fig. 4.6). The 
differential response of de-novo produced proteins is very curious, and at this juncture we 
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do not have a mechanistic explanation. However, the ability of IL-6 to induce the 
production of some proteins and enhance the release of others most likely has to do with 
the expression of response elements within the promoters of these genes. Additional 
mechanistic studies are required to characterize this response. Another important 
observation made during the course of this study was that human skin mast cells 
spontaneously release significant amounts of VEGF, IL-8, and MCP-1. The spontaneous 
release of VEGF in mast cells is not novel, but this is the first reported unstimulated 
production of IL-8 and MCP-1 in human mast cells (149).   
 IL-6’s ability to potentiate spontaneous VEGF production independently of 
FcεRI XL is a significant finding, as VEGF is one of the most potent pro-angiogenic 
factors. In fact, when viewed separately VEGF, IL-8, and MCP-1 all have unique 
physiological functions. But when viewed collectively, all three proteins play important 
roles in angiogenesis. IL-8 is known to be associated with increased microvessel density 
within tumors, while MCP-1 has been shown to promote angiogenesis in human 
umbilical vein endothelial cells (HUVEC) by inducing MCP-1 inducible protein 
(MCPIP) (150, 151). Additionally, mast cell-derived IL-8 has been shown to induce EMT 
in thyroid cancer cells (152).  
In summary, we show here that IL-6 potentiates FcεRI-dependent PGD2 
production and induces VEGF and MCP-1 release. Additionally, IL-6 enhances FcεRI-
dependent VEGF and IL-8 production. Together, this data shows that IL-6 may 
contribute to human allergic disease by increasing the production of inflammatory PGD2 
released by pulmonary-resident mast cells, exacerbating asthmatic disease progression. 
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Finally, the ability of IL-6 to increase angiogenesis-associated VEGF, IL-8, and MCP-1 
release suggests a role for mast cells in developmental and pathological vessel growth.
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CHAPTER 8 
MATERIALS AND METHODS- HUMAN SKIN MAST CELLS 




Angiogenesis is defined as the formation of new vessels from pre-existing ones, 
and serves vital physiological and pathological purposes. Vessel growth is required 
during normal organism development, and is indispensable during tumor formation and 
growth. Mast cells are known to be produces of VEGF, a potent stimulator of 
angiogenesis. There is strong evidence that mast cells participate in pathological vessel 
growth, and they have been shown to induce endothelial cell proliferation, migration, and 
loop and tube formation. However, to better understand the role of mast cells in 
angiogenesis, we sought to profile their secretion of angiogenesis-associated factors.  The 
methods used in this study were designed to identify spontaneous angiogenesis-
associated protein production by human mast cells and investigate the effects of c-Kit and 
FcεRI signaling on their release. All experiments were performed using in-situ-matured 
human skin mast cells isolated in accordance with the University of South Carolina’s 
Internal Review Board (IRB).  
8.1 ISOLATION AND PURIFICATION OF HUMAN SKIN MAST CELLS 
 As described in Section 2.1. 
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 Parts of this chapter have been excerpted from the following research article: 
McHale, C., Mohammed, Z., Gomez, G. 2018. Human skin mast cells spontaneously secrete 
angiogenesis-related factors. (In preparation). 
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8.2 PROTEOME PROFILER 
Mast cells (10
6
 cells/ml) were sensitized or not with anti-NP IgE, pre-treated or 
not with IL-6 (100 ng/ml) for one hour, and then activated or not with NP-BSA for 24 h 
at 37
o
C in X-VIVO 15™ media containing SCF (100 ng/ml) and soybean trypsin 
inhibitor (100 μg/ml) (SBTI; Sigma-Aldrich, St. Louis, MO).  After the activation period, 
mast cells and media were separated by centrifugation (2000 rpm x 5 min), and secreted 
proteins in supernatant were measured by R&D Systems Angiogenesis Proteome Profiler.  
First, the stamped identification number tab on each blot was removed to prevent 
background fluorescence. After removing the protective sheets, membranes were blocked 
in the provided wells with 2.0 mL of Array Buffer 7 for 1 hour on a rocking platform. 
During blocking, sample is prepared by combining 0.75 mL of cell-free supernatant with 
0.5 mL Array Buffer 4. Sample is then adjusted to a final volume of 1.5 mL with the 
addition of 0.25 mL Array Buffer 5. Once each sample is prepared, 15 uL of Detection 
Antibody Cocktail is added, mixed well, and incubated at RT for one hour. After 
blocking is complete, Array Buffer 7 was aspirated from the wells and replaced with the 
incubated sample/antibody mixture described above. The membrane is then incubated in 
the sample/antibody mixture at 4 degrees C overnight on a rocking platform. After 
overnight incubation, individual membranes were removed from the wells and placed in 
separate plastic dishes with 20 mL of Wash Buffer each. The membranes were then 
washed for 10 minutes on a rocking platform shaker. After aspirating off the Wash 
Buffer, this was repeated two times with fresh buffer for a total of three washes. IRDye 
800CW Streptavidin (LI-COR) was then diluted 1:2000 in Array Buffer 5, and 2 mL of 
the diluted antibody was pipetted into each well to be used for staining.  The membranes 
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were then removed from the plastic dishes used for washing, and excess Wash Buffer 
allowed to drain by blotting the lower edge onto absorbent paper. The membranes were 
added to the wells containing antibody and stained in the dark for 30 minutes at room 
temperature on a rocking platform. After secondary staining, the membranes were 
washed as described above. The membranes were then removed from the wash container, 
excess Wash Buffer was drained by blotting the lower edge on absorbent paper, and 
imaging performed on an Odyssey Imager (LI-COR) at 84 μM Resolution, Medium 
Quality, 0.0 mm Focus Offset, and 5 Intensity (adjusted as necessary). Image files were 
then analyzed using Image Studio Version 3.1 (LI-COR) by comparing relative mean 
fluorescence intensities from duplicate samples.  
8.3 SECRETED PROTEIN ELISA 
Mast cells (10
6
 cells/ml) were sensitized with anti-NP IgE and activated or not 
with NP-BSA for 24 h at 37 °C in X-VIVO 15™ media containing SCF (100 ng/ml) and 
soybean trypsin inhibitor (100 μg/ml) (SBTI; Sigma-Aldrich, St. Louis, MO). After the 
activation period, mast cells and media were separated by centrifugation 
(2000 rpm × 5 min), and the indicated proteins in supernatant were measured by using 
commercial DuoSet enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, MN) according to the manufacturer's protocol. Absorbance values at 
450 nm were obtained with a BioTek Synergy HT microplate reader (BioTek, Winooski, 
VT), and cytokine concentrations determined using Gen5 Data Analysis Software. 
8.4 STATISTICAL ANALYSIS 
 As described in Section 2.8.
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CHAPTER 9 




 Mast cells are known for their ability to produce and release a wide variety of 
mediators into their environment. Stimulation by allergen, bacteria, and many other 
compounds trigger this release in addition to the spontaneous release of select proteins. 
This study was designed to identify and catalog the angiogenesis-related proteins 
produced by human skin mast cells, based on their established spontaneous production of 
VEGF, IL-8, and MCP-1 (153). 
9.1 HUMAN SKIN MAST CELLS SPONTANEOUSLY SECRETE 
ANGIOGENESIS-RELATED FACTORS 
Human mast cells derived in culture from umbilical cord blood have been shown 
to spontaneously secrete VEGF (149).  In our studies, we also detect high levels of VEGF 
from non-activated mast cells that were isolated and purified from human skin tissue 
(153). To determine if other angiogenesis-related proteins were also secreted unprompted 
from in situ-matured mast cells, human skin mast cells were washed and cultured in 
serum-free medium containing only stem cell factor (SCF) and soybean trypsin inhibitor 
(SBTI) to prevent proteolysis of secreted proteins (100).  After a 24 h incubation period, 
the cell-free medium was analyzed with the Human Angiogenesis Proteome Profiler™ 
Array (R&D Systems), which enabled us to detect the relative expression of 55 different 
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angiogenesis-related proteins.  To our surprise, several proteins – CXCL16, 
DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP-
1, Thrombospondin-1, uPA, and VEGF – were detected at relatively high levels (Figure 
9.1). 
To confirm the findings from the proteome array analysis and quantify the amount 
of protein secreted, we cultured human skin mast cells in serum-free medium containing 
SCF and SBTI for 24 h, and measured IL-8, VEGF, MCP-1, GM-CSF, TIMP-1, and 
Serpin F1 with ELISA.  As shown, all proteins analyzed were clearly detected (Figure 
9.2).  Noteworthy, TIMP-1 was produced at the highest quantities mirroring the signal 
intensity of the proteome array, whereas VEGF was detected at the lowest level. 
 To determine if the spontaneously secreted proteins accumulate in the medium of 
standard cultures to which SBTI is not normally added, we collected the medium from 
established cultures of resting skin mast cells during regular weekly (every 7 days) 
medium change and measured IL-8, VEGF, MCP-1, GM-CSF, TIMP-1, and Serpin F1 
with ELISA.  IL-6 and TNF were analyzed as positive and negative controls based on 
previous studies (71, 153).  As shown, all the proteins that were detected in the presence 
of SBTI were also detected in the absence of proteolysis inhibitor (Figure 9.3).  Some 
variability was observed and some cultures appeared to produce very low to undetectable 
amounts of a particular protein.  This could be reflective of increased susceptibility to 
proteolysis in the absence of SBTI and/or differences in cell density at the time the 
medium was collected or age of the culture.  Noteworthy, TIMP-1 and Serpin F1 were 
detected at extremely high concentrations from all cultures tested.  Thus, the secreted 
proteins accumulate in cultures of human skin mast cells even in the absence of SBTI.  
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Together these data demonstrate that several angiogenesis-related proteins in addition to 
VEGF are spontaneously secreted from human in situ-matured skin mast cells.  
9.2 DEPENDENCE ON STEM CELL FACTOR 
Mast cell survival is dependent on Kit signals (10).  To determine if the secretion 
of the angiogenesis-related factors was due to stimulation of Kit receptor by exogenously 
added SCF, we cultured human skin mast cells in medium containing SBTI without and 
with SCF (100 ng/ml) for 24 h, and analyzed the cell-free medium by proteome array as 
in Figure 9.1.  As shown in Figure 9.4, secretion of CXCL16, DPPIV, and uPA was 
similar in the presence or absence of SCF whereas secretion of endothelin-1, GM-CSF, 
IL-8, MCP-1, and VEGF was almost completely abolished in the absence of SCF.  In 
addition, secretion of Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, and Thrombospondin-1 
was significantly reduced, but nevertheless produced at high levels in the absence of 
SCF.  These data demonstrate that the secretion of some proteins, but not others, could be 
due to SCF stimulation of Kit receptor.  However, because mast cells require SCF for 
survival, the reduced production of these proteins could be reflective of diminished 
cellular function overall in the absence of the SCF-induced survival signal.   
9.3 EFFECT OF FCΕRI CROSSLINKING ON SECRETION OF 
ANGIOGENESIS-RELATED PROTEINS 
Mast cell activation is generally associated with FcεRI crosslinking.  To 
determine the effect of FcεRI crosslinking on secretion of angiogenesis-related proteins 
particularly those found to be spontaneously secreted, we performed a proteome array 
analysis on medium collected from anti-DNP IgE-sensitized human skin mast cells that 
were challenged with DNP-HSA (100 ng/ml) for 24 h.  As expected, FcεRI crosslinking 
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further increased the production of GM-CSF, IL-8, Serpin E1, and VEGF, and induced 
the production of others like Amphiregulin and MMP-8 (Figure 9.5A).  Surprisingly, 
CXCL16, Endothelin-1, Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin-3 were 
significantly inhibited by FcεRI crosslinking (Figure 9.5B).  To confirm the array data, 
we repeated the experiment and measured IL-8, VEGF, TIMP-1, GM-CSF, Serpin F1, 
and MCP-1 with ELISA.  As shown, IL-8, VEGF, TIMP-1, and GM-CSF were increased 
following FcεRI crosslinking, whereas Serpin F1 and MCP-1 production was inhibited 
(Figure 9.6).  Thus, FcεRI crosslinking has positive and negative effects on production of 
angiogenesis-related factors from mast cells. 
9.4 EFFECT OF GP130 SIGNALING ON SECRETION OF ANGIOGENESIS-
RELATED PROTEINS  
 We have previously shown that human skin mast cells spontaneously secrete 
measureable quantities of VEGF and IL-8 (153) in addition to MCP-1 (not shown). 
Moreover, IL-6 signaling through gp130 increases the spontaneous production of VEGF 
and MCP-1 while potentiating the FcεRI-dependent release of IL-8. To determine the 
effect of IL-6 on the secretion of other angiogenesis-related proteins, we performed a 
proteome array analysis on medium collected  from human skin mast cells that were 
cultured with exogenous IL-6 (100 ng/ml) for 24 h. As expected, gp130 signaling 
increased the spontaneous production of VEGF (Figure 9.7A) and MCP-1 (Figure 9.7B) 
without affecting IL-8 secretion (not shown). Surprisingly, IL-6 did not significantly 
affect secretion of any other proteins detected. Thereby, exogenous IL-6 increases 






Figure 9.1: Human skin mast cells spontaneously secrete angiogenesis-related factors. 
Skin mast cells were cultured at 10
6
/ml for 24 h with SCF (100 ng/ml) and SBTI (100 
μg/ml). Supernatant was then subjected to the Human Angiogenesis Proteome Profiler 
Array (R&D Systems) to allow for the detection of up to 55 different angiogenesis-
related proteins. Bars represent mean ± SEM of two experiments using cells from 




























Figure 9.2: Human skin mast cells spontaneously secrete IL-8, VEGF, MCP-1, TIMP-1, 
GM-CSF, and Serpin F1. Human skin mast cells were cultured in serum-free medium 
containing SCF and SBTI for 24 h, and the indicated proteins were measured by ELISA. 
Data points represent protein concentrations from cultures obtained from three individual 























Figure 9.3: Angiogenesis-related factors accumulate in medium of standard cultures 
without SBTI. Medium from established cultures of resting human skin mast cells with 
added SCF (100 ng/ml) only was collected during regularly weekly (every 7 days) 
feeding. The resulting supernatants were subjected to ELISA for the measurement of the 
indicated secreted proteins. Data points represent protein concentrations from cultures 












Figure 9.4: c-Kit signaling differentially regulates angiogenesis-related protein 
production from human skin mast cells. To determine the effect of SCF on protein 
production, skin mast cells were cultured for 24 hr at 10
6
/ ml plus SBTI (100 μg/ml) with 
or without SCF (100 ng/ml). Supernatant was then subjected to the Human Angiogenesis 
Proteome Profiler Array (R&D Systems) to allow for the detection of 55 different 
angiogenesis-related proteins. Bars represent mean ± S.E.M. of values from 2 separate 
experiments with mast cells obtained from i donors. Significance was determined by 

















Figure 9.5: FcεRI signaling differentially regulates angiogenesis-related protein 
production from human skin mast cells. To determine the effect of IgE receptor 
crosslinking on protein production, skin mast cells were cultured for 24 hr at 10
6
/ ml plus 
SCF (100 ng/ml) and SBTI (100 μg/ml) with or without antigen challenge (NP-BSA 100 
ng/ml). Supernatant was then subjected to the Human Angiogenesis Proteome Profiler 
Array (R&D Systems) to allow for the detection of secreted protein. Bars represent 
mean ± S.E.M. of values from 2 separate experiments with mast cells obtained from 
individual donors. Significance was determined by Student's t-test. *p < 0.05, **p < 0.01, 





















Figure 9.6: FcεRI crosslinking has opposing effects on spontaneous angiogenesis-related 
protein production from human skin mast cells. To verify the results seen in the Proteome 
Profiler, cells were cultured for 24 hr at 10
6
/ ml plus SCF (100 ng/ml) and SBTI (100 
μg/ml) with or without antigen challenge (NP-BSA 100 ng/ml). Supernatant was then 
subjected to the indicated ELISAs to quantify the previously observed effects. Linked 
data points represent protein concentrations from cultures obtained from individual 

















Figure 9.7: IL-6 signaling increases spontaneous VEGF and MCP-1 production from 
human skin mast cells. To determine the effect of IL-6 on protein production, skin mast 
cells were cultured for 24 hr at 10
6
/ ml plus SCF (100 ng/ml) and SBTI (100 μg/ml) with 
or without IL-6 (100 ng/ml). Supernatant was then subjected to the Human Angiogenesis 
Proteome Profiler Array (R&D Systems) for protein detection. Bars represent 
mean ± S.E.M. of values from 2 separate experiments with mast cells obtained from 













Mast cells are believed to play a key role in angiogenesis. Current knowledge 
suggests that mast cells contribute to vessel growth by producing and releasing several 
angiogenesis-related proteins including VEGF, FGF, IL-8, TIMPs, and basement-
membrane degrading enzymes (96). Both VEGF and FGF are particularly potent inducers 
of angiogenesis, enacting their effects even at low levels (154). At present, researchers 
have identified dozens of proteins outside of those mentioned that are involved in the 
regulation of angiogenesis. However, data on the full range of angiogenesis-related 
proteins produced by mature human mast cells is deficient. We previously showed that 
human skin mast cells spontaneously produce VEGF, IL-8, and MCP-1, suggesting an 
unexplored role for mast cells in vessel growth (153). Thus, the goal of the present study 
was to identify and catalog the production of angiogenesis-related proteins by in-situ-
matured human skin mast cells.  
Our lab’s unique ability to isolate and culture in-situ matured human mast cells 
again afforded us the opportunity to study cells that were differentiated and matured in 
physiological conditions. For this reason, we can confidently draw parallels between how 
our human skin mast cells function in-vitro and how they may function in-vivo. This is in 
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stark contrast to using a mouse bone marrow-derived mast cell, mast cell line 
(HMC-1, LAD2) or even a human CD34+ cord blood-derived mast cell (CBMC), which 
are artificially differentiated. These in-vitro-matured MCs can have marked differences 
from in-situ-matured cells, ranging from disparities in relative mediator production to 
lacking surface expression of the cell type-defining IgE receptor FcεRI (112). Using this 
model, we demonstrate that resting in-situ-matured human skin mast cells spontaneously 
secrete CXCL16, DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1, 
Serpin F1, TIMP-1, Thrombospondin-1, uPA, and VEGF (Table 10.1). Furthermore, 
production of these factors is differentially regulated by both c-Kit and FcεRI signaling. 
 
Table 10.1: Spontaneously produced angiogenesis-associated proteins from huSMCs. 
Protein  Gene ID Alternate Nomenclature 
CXCL16 58191  
DPPIV 1803 CD26 
Endothelin-1 1906 ET-1 
GM-CSF 1437  
IL-8 3576 CXCL8 
MCP-1 6347 CCL2 
Pentraxin 3 (PTX3) 5806 TSG-14 
Serpin E1 5054 PAI-1 
Serpin F1 5176 PEDF 
TIMP-1 7076  
Thrombospondin-1 7057 TSP-1 
uPA 5328  
VEGF 7422  
 
To create this profile of angiogenesis-related proteins produce by mature human mast 
cells, we approached this study with an inverted pyramid strategy; beginning by testing 
for a wide variety of mediators and then using this profile to narrow down specific 
protein targets. To do this, we employed the use Human Angiogenesis Proteome 
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Profiler™ (R&D Systems). Allowing for the identification of up to 55 proteins at a time, 
these assays utilize a membrane coated with sets of specific capture antibodies to identify 
multiple proteins of interest in a western blot-like manner. The resulting output is 
twofold: (1) whether or not the cell type is producing each protein, and (2) the relative 
amount of secreted protein. Since this assay does not quantify the concentration of each 
factor, the Proteome Profiler data is best interpreted when confirmed by quantifiable 
methods such as ELISA. 
As aforementioned, our initial goal was to identify spontaneous release of 
angiogenic proteins by resting human skin mast cells. After culturing cells from multiple 
donors in serum-free media with only added SCF (100 ng/ml) and SBTI (100 μg/ml) for 
24 hours, the resulting supernatant was subjected to the Proteome Profiler. The Profiler 
determined spontaneous secretion of CXCL16, DPPIV, Endothelin-1, GM-CSF, IL-8, 
MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, Thrombospondin-1, uPA, and 
VEGF. Notably, the relative levels of expression appeared to be highly variable from 
protein to protein. Some factors, such as TIMP-1, were present in robust amounts, 
whereas other factors like VEGF and uPA appeared at fractional levels of TIMP-1. Also 
of note is that these proteins are a mix of pro- and anti-angiogenic factors, suggesting a 
role for mast cells in the regulation of angiogenesis rather than just its initiation and 
perpetuation. We confirmed the findings from the profiler array by performing ELISAs 
on cell-free supernatants from human skin mast cells cultured for 24 h in serum-free 
media with SCF (100 ng/ml) and SBTI (100 μg/ml). As shown in Figure 7.2, IL-8, 
VEGF, MCP-1, GM-CSF, TIMP-1, and Serpin F1 were all detectable by ELISA. As in 
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the profiler, TIMP-1 was produced at the highest concentrations compared to the other 
proteins.  
In addition to the secretion of de-novo produced proteins and biosynthesized 
eicosanoids, mast cells also release the contents of their cytoplasmic granules upon FcεRI 
XL activation. It was shown that mast cells sometimes spontaneously release these 
granules and the compounds contained within them, including proteases (155). 
Importantly, these endogenous proteases have been proven to be responsible for the 
degradation of mast cell-produced cytokines (100). To determine if the spontaneously 
secreted proteins accumulate in the media of human skin mast cells without added SBTI, 
we collected the media from established cultures during weekly feedings (occurs every 7 
days). ELISA revealed that all proteins detected in the presence of SBTI- IL-8, VEGF, 
MCP-1, GM-CSF, TIMP-1, and Serpin F1, were detectable in the absence of the 
proteolytic inhibitor SBTI. This shows that these proteins are not subject to degradation 
by endogenous mast cell proteases, or are only slightly susceptible to digestion. While 
there were significant differences in the concentrations of proteins from culture to 
culture, this can be attributed to disparity in cell concentration, culture age, and 
susceptibility to proteolysis.   
 The presence of so many spontaneously produced proteins in the supernatant of 
resting mast cells was a surprising discovery that merited further investigation. Since the 
media used contains no serum or growth factors outside of the required SCF, we sought 
to determine the involvement of c-Kit (SCFR) signaling in angiogenesis-related protein 
production. It is known that SCF plays an important role in mast cell activation and pro-
inflammatory mediator release, so it possible that c-Kit signaling contributes to 
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angiogenesis-related protein secretion (15). Cells were incubated for 24 in serum-free 
media plus SBTI (100 μg/ml) with or without SCF (100 ng/ml). After incubation, the 
cell-free supernatants were subjected to the Proteome Profiler. Comparison of protein 
secretion in SCF compared to media only samples revealed an interesting effect; c-Kit 
signaling differentially regulates the production of each protein. CXCL16, DPPIV, and 
uPA production is SCF-independent, Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, and 
Thombospondin-1 production is partially SCF-dependent, and GM-CSF, IL-8, MCP-1, 
and VEGF production is SCF-dependent. This discovery further emphasizes the 
importance of SCF in mast cell function, and reinforces the idea that it is a critical 
molecule for mediator production (15). While this is an interesting mechanism to 
consider, ultimately the point is moot because SCF is required for mast cell expansion, 
differentiation, and survival (7). Without added SCF in vitro, both human and murine 
mast cells will lose function, viability, and ultimately perish (10). Thus, the effects of c-
Kit signaling on protein production in the absence of SCF are irrelevant. 
 Knowing that human skin mast cells spontaneously produce measurable quantities 
of angiogenesis-related proteins, the logical next step was to investigate how allergic 
activation modulates this function. To achieve this, we challenged IgE-sensitized human 
skin mast cells with NP-BSA or media control and cultured them for 24 h in serum-free 
media plus SCF (100 ng/ml) and SBTI (100 μg/ml). The cell-free supernatants were 
again subjected to the Proteome Profiler and the FcεRI XL samples were compared to 
spontaneous controls. Analysis revealed that FcεRI XL differentially regulated 
angiogenesis-related protein production. Protein secretion was increased, decreased, or 
remained unaffected. Those increased by IgE-receptor crosslinking included 
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Amphiregulin, GM-CSF, IL-8, TIMP-1, and Serpin E1, while CXCL16, Endothelin-1, 
Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin 3 were decreased. The increases in 
the production of the aforementioned factors were not surprising, as it is well-
documented that FcεRI XL induces the release of many de-novo synthesized proteins 
(28). However, the reduction in MCP-1 and Serpin F1 levels upon allergic activation is a 
novel observation since there is currently no evidence for IgE receptor crosslinking 
decreasing mediator production. To confirm the results of the Proteome Profiler, we 
repeated the experiment and assayed the cell-free supernatants for the indicated proteins 
by ELISA. We validated the increases in seen in IL-8, VEGF, TIMP-1, and GM-CSF 
upon FcεRI XL, and the decreases seen in Serpin F1 and MCP-1. The consequences of 
FcεRI XL on angiogenic mediator production are interesting to consider, especially due 
to the wide range of functions performed by the affected proteins. For example, FcεRI 
XL increases VEGF, which induces potent endothelial proliferation and promotes 
angiogenesis (156). Conversely, TIMP-1 production is also increased by FCεRI XL, yet 
TIMP-1 functions to hamper angiogenesis by inhibiting the proteases responsible for 
degrading the basement membrane (157). Even the decrease in MCP-1 and Serpin F1 
upon FcεRI tell a dichotomous story, as MCP-1 is strongly angiogenic due to its 
induction of the transcription factor MCP-1 induced protein (MCPIP) (151), while Serpin 
F1 inhibits vessel growth by decreasing VEGFR expression (158). These seemingly 
opposing effects again suggest that mast cells may play a regulatory role in vessel 
growth, perhaps serving to both initiate and attenuate angiogenesis. This contrasts with 
the general current view that mast cells serve a primarily pro-angiogenic purpose in-vivo 
(96). A more nuanced role for mast cells in angiogenesis would not be surprising since 
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vessel growth is ubiquitously associated with several diseases in which mast cells have 
been implicated (3, 80, 159). Specifically, angiogenesis is a hallmark of pathology in 
asthma where vessel growth occurs during airway remodeling (160). During asthmatic 
airway remodeling, the local balance of pro- and anti-angiogenic factor expression shifts 
heavily towards pro-, including increased local VEGF expression and concentration (161, 
162). Similarly, increased levels of VEGF and Serpin F1 are present in children who 
suffer from chronic food allergy compared to non-allergic individuals (163). While mast 
cells have been inculpated as a source of this increased VEGF, our results suggest they 
contribute much more to the local tissue (153).  
Our final goal was to examine the effect of gp130 signaling, specifically via IL-6, 
on angiogenesis-related protein production. Increased IL-6 levels are associated with 
many inflammatory conditions including allergic disease and cancer, where angiogenesis 
is key to tumor growth(54). We had previously shown that IL-6 signaling alone increased 
human skin mast cell spontaneous production of VEGF and MCP-1, and potentiated 
FcεRI-XL-dependent IL-8 release. Supporting this notion, IL-6 has been shown to 
increase VEGF production in many studies, particularly those involving cancerous cells 
or tumors (164–166). To investigate how IL-6 modulates angiogenic protein release in 
human skin mast cells, we cultured cells for 24 h in media with or without IL-6 (100 
ng/ml) plus SCF (100 ng/ml) and SBTI (100 μg/ml). The resulting cell-free supernatant 
was subjected to the Proteome Profiler, and relative protein levels were compared 
between IL-6-treated and control samples. Surprisingly, activation by IL-6 only revealed 
increases in the production of VEGF and MCP-1, corroborating our previous 
observations (153). While this data reaffirms the effects of IL-6 signaling on human skin 
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mast cell VEGF and MCP-1 production, we failed to identify any new angiogenesis-
associated targets of gp130 signaling. MCP-1 induced protein (MCPIP) appears to be 
directly linked to VEGF production as knocking it down results in decreased VEGF and 
HIF-1 expression (151). Additionally, MCP-1 was shown to promote tumor metastasis in 
murine breast cancer cells (167).  This suggests the possibility of a novel mechanism of 
IL-6-mast cell-MCP-1-induced angiogenesis.  
 Collectively, this study proves that in-situ matured human skin mast cells: (1) 
spontaneously produce significant amounts of angiogenesis-related proteins, (2) FcεRI 
XL differentially regulates this spontaneous production, and (3) IL-6 signaling 
significantly enhances the spontaneous production of VEGF and MCP-1. These data 
taken together strongly suggest a major regulatory role for mast cells in angiogenesis, and 
further expand the known repertoire of human mast cell mediators. The wide range of 
angiogenesis-associated proteins produced shows that we must now consider mast cells 
as contributing to both the initiation and attenuation of vessel growth. Finally, due to 
increased mast cell numbers in the tumor microenvironment and the importance of vessel 
growth during tumor progression and metastasis, this data advocates a renewed 




The data discussed here represents a new understanding of mast cell function in 
both allergic and non-allergic disease. Most significantly, we have characterized a novel 
IL-6 signaling pathway in in-situ matured human skin mast cells and reported its effects 
on mediator production. In a STAT-3-dependent manner, IL-6 potentiates PGD2 
biosynthesis by upregulating COX-2 expression. While IL-6 has no effect on 
degranulation, it does increase production of spontaneous VEGF and MCP-1 while 
potentiating FcεRI-XL-dependent IL-8 production. Mechanistically, we have shown that 
simultaneous antigen challenge and administration of IL-6 phosphorylates both the Y705 
and S727 residues on STAT-3, required for its maximal transcriptional activity. The 
ubiquity of IL-6’s presence during inflammatory conditions such as allergic disease, 
rheumatoid arthritis, and obesity represents a new link to how mast cells may contribute 
to these diseases. Importantly, this study also provided us with the knowledge that human 
skin mast cells spontaneously produce significant amounts of VEGF, MCP-1, and IL-8- 
all angiogenesis-associated factors. 
We next demonstrated that mast cells, in addition to VEGF, MCP-1, and IL-8, 
spontaneously produce substantial amounts of several angiogenesis-related proteins. This 
finding, in addition to the well-known fact that mast cells are found proximally to blood 
vessels, suggests a role for mast cells in both developmental and pathogenic 
angiogenesis. Moreover, we showed that the production of these angiogenesis-related 
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proteins can be differentially by FcεRI XL. FcεRI increased the release of 
Amphiregulin, GM-CSF, IL-8, and Serpin E1, but decreased production of CXCL16, 
Endothelin-1, Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin 3. These effects of 
allergic activation further enforce a potential role for mast cells in vessel growth.  
Finally, we show opposing effects of the polyphenol Resveratrol on pro-
inflammatory mediator production in human skin mast cells. At low concentration, 
Resveratrol inhibited PGD2 biosynthesis but significantly enhanced TNFα production. 
These antagonistic effects emphasize the importance of understanding the full spectrum 
of consequences that Resveratrol could have on inflammation. While it may be effective 





Our current model of isolating and culturing in-situ-matured human skin mast 
cells to purity is the most accurate in-vitro representation of this cell type’s behavior in 
the human body. However, this still means that the findings detailed in this Dissertation 
exclusively address the in-vitro behavior of mature human mast cells. The logical next 
step is to adapt these findings to in-vivo mouse models.  
We have shown that both IL-6 and Resveratrol affect PGD2 production, which has 
been chiefly implicated in the pathogenesis of asthma. It follows that examining the 
effects of IL-6 and Resveratrol in a mouse model of asthma, such as in the ovalbumin-
induced model, would be appropriate. Conversely, one could take many different 
approaches to investigating the effects of mast cells on angiogenesis in-vivo. In 
particular, the use of a mouse model of cancer (of which there are many) to study 
pathological angiogenesis could prove exceptionally fruitful.  
The IL-6 signaling pathway in human skin mast cells still requires further 
elucidation in which our in-vitro model will be useful. There are undoubtedly many more 
targets of IL-6 signaling, and a microarray or BioPlex would be an efficient way to 
determine additional IL-6-responsive genes. We would also like to investigate the ability 
of human skin mast cells to produce soluble IL-6Rα and gp130, which can be 
accomplished by ELISA. Understanding the contributing of mast cells to local and 
systemic IL-6 signaling could prove vital in targeting this pathway during clinical anti-
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inflammatory intervention. Finally, since recent emphasis has been put on understanding 
cellular metabolism, we would like to study how IL-6 affects mast cell mitochondrial 
function and glycolysis. With this data, we believe we could produce a specific snapshot 
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